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Abstract 
Reaching the full potential of precision medicine depends on the quality of personalized 
genome interpretation. In order to facilitate precision medicine in regions of the Middle East and 
North Africa (MENA), a population-specific reference genome for the indigenous Arab popula-
tion of Qatar (QTRG) was constructed by incorporating allele frequency data from sequencing of 
1,161 Qataris, representing 0.4% of the population. A total of 20.9 million SNP and 3.1 million 
indels were observed in Qatar, including an average of 1.79% novel variants per individual ge-
nome. Replacement of the GRCh37 standard reference with QTRG in a best practices genome 
analysis workflow resulted in an average of 7* deeper coverage depth (an improvement of 23%), 
and 756,671 fewer variants on average, a reduction of 16% that is attributed to common Qatari 
alleles being present in the QTRG reference. The benefit for using QTRG varies across ances-
tries, a factor that should be taken into consideration when selecting an appropriate reference for 
analysis. 
 Introduction 
 Precision medicine involves tailoring medical decision making to genomic individuality 
in the context of an individual’s unique environment/lifestyle1. Early examples of successful ap-
plication of precision medicine include cancer, where sequencing of the patient and tumor ge-
nomes can identify specific targets for therapeutic decisions2, and rare disease, where sequencing 
can lead to the rapid discovery of causative mutations and correct diagnosis in a time-critical 
clinical setting3. For the latter, while the cost of sequencing an individual’s genome has declined 
rapidly in the past 1.5 decades, there are still considerable challenges for genome interpretation, 
such as important variants being missed due to low coverage or incorrect calls, and the emerging 
challenge of interpreting a growing number of variants of unknown significance in each human 
genome. With over 3 million SNPs identified per human genome sequenced, the majority of 
these variants cannot be immediately linked to a known phenotype, and the putative impact of 
variants must therefore be inferred computationally using algorithms that harness comparative 
genomics and available experimental data4-6. Thus, precision medicine in the near term stands to 
benefit greatly from both increased accuracy in variant calling and improved interpretability 
when the aim is to identify variants of relevance to one or more phenotypic manifestations within 
an individual, family of related individuals, or population.  
 Reference bias is a known issue in human genome resequencing for variant detection7, 
and modifications to the reference can improve calling accuracy and interpretability8. Relevant to 
the issue of variant calling accuracy, a reference that more closely matches the ancestry of the 
genome(s) being aligned is expected to reduce mismatches during alignment and lead to more 
accurate genotypes8. Applicable to the issue of interpretability of variants for rare disease is the 
observation that a variant’s prevalence is inversely proportional to the variant’s deleterious im-
pact on cellular function (and by extension, evolutionary fitness), with the most severely delete-
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rious variants being the rarest due to purifying selection9. Based on this principle, the American 
College of Medical Genetics (ACMG) recommends excluding any allele above 5% prevalence 
from consideration as pathogenic10. Given that allele frequency is a population-dependent prop-
erty (e.g., an allele that is rare in one population may be common in another), relying entirely on 
the standard reference genome (GRCh37) or allele frequency in ethnically mismatched popula-
tions (even if a large sample of individual genomes has been sequenced) may produce incorrect 
assessments of the pathogenicity of a specific allele in an under-studied population.    
 One approach to improving both variant calling accuracy and interpretability of an indi-
vidual’s genome is to incorporate variant prevalence information early on in the genome inter-
pretation process by modifying the reference genome, such that variants discovered in the ge-
nome are the minor allele in the population8. This modification to the reference results in a 
streamlined analysis workflow, as fewer variants need to be interpreted. In this context, it should 
be of value to produce a separate major allele reference genome for each distinct ancestral popu-
lation or regional meta-population, particularly in cases when the genomic variation in these 
populations has not been well sampled in public databases. 
 The region of the Middle East and North Africa (MENA) is an example of such an under-
studied meta-population where the rising adoption of precision medicine could benefit greatly 
from a specific major allele reference genome. In particular, this region is characterized by a 
high prevalence of consanguineous marriage and elevated incidence of certain Mendelian disor-
ders, and thus is a region where numerous disease studies are faced with the problem of too 
many potential disease variants per sequencing experiment11. Such a region would undoubtedly 
benefit from allele frequency databases of ethnically matched controls. In addition, given the di-
versity of the region, many variants called in the population relative to the current reference ge-
nome may in fact be the major allele in the population, and eliminating these from being called 
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would lead to a more efficient analysis.  
 To produce a first version of a reference genome tailored to the region, we sampled and 
sequenced genomes from Qataris, an indigenous population located near the center of the MENA 
region. The current population of the nation of Qatar includes over 1.7 million expatriates pri-
marily from MENA and South Asia that have arrived in recent decades12, and ~300,000 Qataris 
of indigenous ancestry who arrived in prior waves of migration. At the genome level, the ethnic 
Qataris represent a population with a mixture of Bedouin/Arab (Q1), Persian/South Asian (Q2) 
and African (Q3) ancestry13,14. In particular, the Bedouin/Arab (Q1) subpopulation, with deepest 
ancestral roots in the Peninsula, continue to practice within-tribe marriage that has led to a high 
level of homozygosity compared to other populations worldwide14,15.   
 In order to demonstrate the value of a reference genome tailored to an indigenous popula-
tion in the MENA region, we have constructed a Qatari Reference Genome (QTRG) where the 
reference bases are “flipped” to the Qatari major allele. The value and utility of QTRG with re-
spect to the standard reference (GRCh37) was evaluated in several ways on genomes not used to 
construct the QTRG. In the field of population genomics, the term “n+1 genome” refers to the 
“next” genome sequenced after a large-scale sequencing effort of n genomes, such as the 1000 
Genomes Project. A major question in population genomics is “what is the benefit of having a 
database of n sequenced genomes when sequencing a single genome not in the database?”, where 
the single genome is referred to as the “n+1” genome. In this study, the value of the database of 
over 1000 sequenced Qatari genomes and exomes is demonstrated, including analysis of over 
n=15 genomes and n=16 exomes from diverse ancestries. Improvements in mapped read depth 
were observed, and the subsequent improvement in variant sensitivity was measured. A catalog 
of known pathogenic variants in Qatar was compiled, with variant coordinates in both the stand-
ard (GRCh37) and modified (QTRG) reference. 
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Methods Summary 
 Human subjects were recruited and written informed consent was obtained at Hamad 
Medical Corporation (HMC) and HMC Primary Health Care Centers in Doha, Qatar under pro-
tocols approved by the Institutional Review Boards of Hamad Medical Corporation and Weill 
Cornell Medical College in Qatar. Briefly, a total of 1,376 subjects were recruited for genome 
(n=108) or exome (n=1,268) sequencing, including a set of 31 sequenced by both methods for 
validation purposes. The exome sequencing included target enrichment using either the Agilent 
SureSelect Human All Exon 38 Mb (n=67) (referred to as Exome38Mb) and Agilent SureSelect 
Human All Exon 51 Mb (n=1201) platforms (referred to as Exome51Mb). Subjects included 
both 3-generation Qataris (n=1,161) and non-Qatari residents of Qatar (n=215), from the general 
Middle East and North Africa (MENA) region or South Asia. Genotypes were generated using 
the GATK Best Practices workflow16. One Qatari female was sequenced on all three platforms, 
as well as a fourth platform (Illumina HiSeq X), and was used for calibration of batch-specific 
filters for data integration. In order to minimize batch-specific variants, a range of batch-specific 
filters were evaluated on genomic intervals in the intersection of the three platforms, and the op-
timal minimum depth and minimum allele count filters were selected, such that the novel SNP 
rate was consistent across batches within genomic intervals covered by the four platforms 
(0.73% novel SNPs), resulting in under 5% batch-specific variants in the quadruple-sequenced 
Qatari. The filters were confirmed to not be overly stringent by assessing the number of coding 
variants (and novel %) across a range of depths in the quadruple-sequenced Qatari, and compar-
ing the before/after filtering total variants and novel SNP rates both across platforms and with 
published reports of a similar analysis17. After application of batch-specific filters, the SNP data 
from the three platforms was integrated using GATK. Using the calls of sites covered in the three 
batches for the n=1376 individuals, population structure analysis was conducted in combination 
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with 1000 Genomes Phase 318 and the Human Origins dataset19 using ADMIXTURE20. Each in-
dividual was assigned to one of 12 ancestral population clusters based on their dominant ances-
try, and the validity of the clustering was confirmed using Principal Components Analysis21. Re-
latedness analysis was conducted using KING22, and first and second degree relatives assessed 
using a liberal cutoff (to assure an unrelated sample) were excluded. Using the remaining 1,005 
unrelated Qataris, including 917 exomes and 88 genomes, allele frequencies at SNPs was calcu-
lated. In addition, indels were called in the 88 genomes using the CASAVA23 pipeline and an 
assessment of size and allele frequency of these variants was also conducted.  
 In order to facilitate genome interpretation for precision medicine in Qatar, major allele 
SNPs and indels were identified, and the GRCh37 reference genome was modified at these sites 
to produce the Qatar Reference Genome (QTRG). At each site in the QTRG reference, the major 
allele in Qatar is the reference allele in the sample of n=1005 unrelated Qataris. Three versions 
of the QTRG were produced, including versions incorporating major allele SNPs (QTRG1), ma-
jor allele indels (QTRG2), and major allele SNPs and indels (QTRG3).  
 In order to select an optimal reference for analysis of n+1 genomes and exomes, the three 
references were compared in terms of mapped read depth. Genome sequence data from the quad-
ruple-sequenced Qatari were mapped to the four references (GRCh37, QTRG1, QTRG2, and 
QTRG3) using BWA24, and the depth of coverage was calculated using GATK for all sites and 
for modified sites. The resulting depth was compared across platforms, and the reference with 
the deepest resulting coverage was selected for further analysis. Further inspection of the value 
of the reference for variant detection was assessed by producing variant calls using GATK Best 
Practices twice, with the only change being the reference genome used. This comparison was 
conducted for the quadruple-sequenced Qatari, a Qatari family of n=15 genomes of Persian an-
cestry, and a diverse panel of n=16 Qatari exomes. The number of variants identified was com-
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pared across references. In order to assess the impact beyond modified variants, the expected re-
duction in variants (based on the number of modified variants in the individual) and the observed 
reduction in variants was compared. 
 An obstacle to using a QTRG reference containing common indels is that the genomic 
coordinates of known variants and genes are shifted. Conversion of coordinates between refer-
ences is conducted using a “liftover”, where the GRCh37 and QTRG chromosomes are aligned 
using progressiveCactus25, and a liftover for known gene and variant positions from GRCh37 to 
QTRG is conducted using HalTools26. This conversion was conducted for variants functionally 
annotated to have a known link to disease and are high priority for future studies of Mendelian 
disease in Qatar. Through a combination of automated and manual curation following the most 
recent ACMG guidelines for next-generation sequencing interpretation10, liftover annotation of 
n=128 pathogenic variants was conducted. For further methodologic details, see Supplemental 
Methods. 
Results 
Data Integration 
 In order to build a reference genome for precision medicine applications in Qatar and the 
greater MENA region where major allele variants are incorporated into the reference sequence, 
n=1161 Qatari and n=215 non-Qatari living in Qatar were sequenced on the Illumina platform in 
three batches (n=108 genome, n=67 Exome37Mb and n=1201 Exome51Mb) to 38* genome 
depth and 70* exome depth. Genotypes were generated for each batch using the GATK Best 
Practices workflow16,27, and combined into a single variant call set after application of batch-
specific filters (see Supplemental Figure 1 for workflow overview). In the integrated call set, the 
novel SNP rate was assessed for genomic intervals covered in all samples, a per-sample mean of 
0.73% in the genome batch and 0.72% in both exome batches (Supplemental Table I). The plat-
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form specific filters evaluated included minimum depth (ranging from 2* to 20*) and minimum 
allele count (ranging from 1 to 6). Increasing minimum depth, but not increasing minimum allele 
count had an effect of increasing the median depth of exome sequencing (Supplemental Figure 
2A), and decreasing the total number of variant sites observed in exome sequencing (Supple-
mental Figure 2B), while neither filter had major impact on the genome sequencing median 
depth nor total variant sites. A minimum depth and minimum allele count was applied to the two 
batches of exome sequence data (Exome38Mb, n=67 and Exome51Mb, n=1201) such that the 
novel SNP rate was the same or lower than the genome rate for 12* minimum depth and mini-
mum allele count 1. At this threshold, the Exome38Mb filter was minimum 12* depth (minimum 
allele count 1), and the Exome51Mb filter was minimum 10* depth (minimum allele count 2) 
(black line in Supplemental Figure 2C).  
 Using a quadruple-sequenced female Qatari as a benchmark, the number of batch-specific 
variants was assessed for all variants and for novel variants before and after application of the 
batch-specific filters (Supplemental Figure 3). All four datasets were analyzed using the same 
pipeline, and a comparison was conducted on CCDS coding intervals covered in all four plat-
forms (within the Exome38Mb target intervals). Before filtering, the rate of batch-specific vari-
ants in the full call set was 10.1% (Supplemental Figure 3A), and an excess of batch-specific 
novel variants (82.6%, Supplemental Figure 3B) was observed. After filtering, the batch-specific 
variant rate was reduced to 4.9% (Supplemental figure 3C), and the rate of batch-specific novel 
variants was considerably reduced (16.8%; Supplemental Figure 3D).  
 The impact of the filters on variant sensitivity and novel SNP rate was assessed across a 
range of mean depth for the four platforms (Supplemental Figure 4). Variant sensitivity increases 
with additional depth, however sensitivity reaches a plateau after 25* depth for genome sequenc-
ing and 65* depth for exome sequencing (Supplemental Figure 4A). Application of batch-
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specific filters reduced the sensitivity of exome sequencing to a greater extent than genome se-
quencing (Supplemental Figure 4B). In terms of novel SNPs, a linear increase in novel variant 
rate was observed with increasing depth across platforms, with the exception of the HiSeq 2500 
genome, which reaches a plateau under 1% (Supplemental Figure 4C). After filtering of the Ex-
ome38Mb and Exome51Mb data, a similar plateau effect was observed for exome data (Supple-
mental Figure 4D). The filters were verified to not be overly stringent, based on the total variants 
per genome or exome in coding regions being in the range of prior studies17. 
Ancestry Analysis 
 Prior studies of the Qatari population have characterized it as a diverse population with 
influences of Arab, Bedouin, Persian, South Asian, and African ancestry28. In order to character-
ize the ancestry of our sample, the n=1161 Qataris (n=108 genomes, n=1053 exomes) were com-
pared to n=215 non-Qataris living in Qatar and sampled by exome sequencing in this study, as 
well as public databases of diverse genomes, including the 1000 Genomes Project18,29 and the 
Human Origins data (described in Supplemental Table II). Using the parameter K=12 (12 ances-
tral populations) that was inferred to be optimal in a prior study28, the ancestral population struc-
ture of the combined sample of n=5661 genomes was analyzed using ADMIXTURE on a set of 
n=2265 SNPs segregating in all four datasets (Qataris, non-Qataris sampled in Qatar, 1000 Ge-
nomes, Human Origins). The proportion of 12 ancestries was determined for each individual, and 
individuals were assigned to a cluster based on the dominant ancestral population in their ge-
nome (Supplemental Figure 5A and Supplemental Table III). The Qataris were assigned to 
7 clusters, determined to be of European (K=1, n=5 Qataris), South Asian (K=4, n=82 Qataris), 
Bedouin (K=5, n=566 Qataris), African Pygmy (K=6, N=1 Qatari), Bedouin (K=8, n=236 Qata-
ris), Persian (K=9, N=194 Qataris), and Sub-Saharan Africa (K=10, n=77 Qataris) (Supplemental 
Table III and Supplemental Figure 5B). Using a color-coding scheme based on the 12 ancestral 
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clusters (Supplemental Table III), a principal components (PC) analysis was conducted for the 
combined set of n=5661 samples. Clearly separation of African and non-African clusters were 
observed when plotting PC1 vs PC2 (Supplemental Figure 6A), and resolution of European, 
Asian and Middle Eastern clusters was observed when plotting PC2 vs PC3 (Supplemental Fig-
ure 6B).  
Relatedness Analysis 
 The Qataris and non-Qataris sampled in this study included a mixture samples from stud-
ies of rare and common diseases, including both families affected with Mendelian disorders and 
a randomly sampled group of presumably unrelated type-2 diabetics and controls. Given the 
within-family sampling and the known high rate of consanguineous marriage in Qatar30, we 
sought to exclude relatives prior to estimation of variant allele frequency in the general Qatari 
population. For this purpose, an analysis of relatedness was conducted on the n=1376 individuals 
sequenced in this study, using SNP variants in genomic intervals covered in the intersection of 
the three batches (within Exome38Mb target intervals). Using an LD-pruned set of n=381028 
SNPs, the relatedness was calculated across all pairs of individuals. A total of n=736 relation-
ships were observed, including n=239 1st degree relationships, n=71 2nd degree relationships, and 
n=526 3rd degree relationships (Supplemental Table IV). The relationships were plotted using 
Cytoscape31, color-coded by inferred ancestry, and the majority of relationships were between 
individuals of the same ancestry. The largest pedigrees recovered were of Middle Eastern (Bed-
ouin, Arab, Persian) ancestry, confirming theories of deep population structure among Qataris 
and within-tribe intermarriage (Supplemental Figure 7). After exclusion of 1st degree and 2nd de-
gree relatives, a total of n=1,005 Qataris remained in the analysis, including n=88 genomes and 
n=917 exomes (n=64 Exome38Mb and n=853 Exome51Mb). 
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Variant Discovery in Qatar 
 The individual variants observed in 1005 Qataris were aggregated and their allele fre-
quency was quantified. After exclusion of relatives and application of batch-specific filters, an 
average of 4,045,064 SNPs were observed per genome (n=88), an average of 15,382 SNPs were 
observed per Exome51Mb (n=853) and an average of 13,538 SNPs were observed per Exo-
me38Mb (n=64). The novel SNP rate was higher in the genome (1.99%) than in the exome, with 
a slightly higher rate in the Exome51Mb (0.99%) than in the Exome38Mb (0.67%) samples. This 
trend is consistent with higher degree of selection on protein coding genes as compared to non-
coding DNA, and the inclusion of transcripts that do not code for protein in the Exome51Mb tar-
gets ( ). The rate of novel variants was higher in ChrX, ChrY, and MtDNA for the genome data, 
possibly due to a bias towards autosomal data in dbSNP (Table I). The SNP data was aggregated 
across platforms, resulting in a total of 20,937,965 SNPs, of which 14.21% were not previously 
observed in dbSNP (as of build 146) (Supplemental Table I). A call set of short indel variants (< 
300bp) was generated for the 88 unrelated Qatari genomes using the CASAVA pipeline, identi-
fying a total of 5,452,613 variants, of which 58.37% were novel. 
Construction of the Qatar Reference Genome 
 The allele frequency was quantified for each SNP, and a total of 1,931,122 (9.22%) of the 
SNPs were present in over half the Qatari alleles sampled, and hence are candidates for modifi-
cation in the Qatar Reference Genome (Supplemental Table V). Furthermore, while prior studies 
of ancestry-specific reference genomes have incorporated major allele SNP variants, the inclu-
sion of major alternate allele (MAA) indel variants has not previously been explored. In order to 
explore the value of incorporating indels into the reference, 1,882,405 MAA indel variants 
(34.52%) were identified (Supplemental Table V).   
 Three versions of the Qatar Reference Genome were constructed, where major alternate 
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alleles (MAAs) were modified. The first version (QTRG1) includes modification of MAA SNPs, 
the second version (QTRG2) includes modification of MAA indels, and the third version 
(QTRG3) includes modification of MAA SNPs and indels. 
Selection of an Optimal Reference for Read Mapping 
 In order to determine which reference produces the greatest improvement in terms of 
mapped read depth, the genome of the quadruple-sequenced Qatari was mapped to the four ref-
erence genomes, including the unmodified reference (GRCh37), and the Qatari references in-
cluding modifications at MAA SNPs (QTRG1), indels (QTRG2), and both SNPs and indels 
(QTRG3). An improvement in mapped read depth was observed for all Qatari references, with 
the greatest improvement (10%) at modified sites when using QTRG3 (Figure 1A). A modest 
improvement in mapped read depth was observed overall, with the benefits extending beyond 
modified sites (Figure 1B).  
Impact of Using Qatar Reference Genome on Variant Sensitivity 
 Increased mapped read depth results in increased sensitivity for variant detection (Sup-
plemental Figure 4A). In order to assess the benefit of improved mapped read depth using 
QTRG3 on variant sensitivity, GATK Best Practices analysis was conducted twice, with the only 
difference between iterations being the reference used (GRCh37 versus QTRG3). This analysis 
was conducted for the quadruple-sequenced Qatari, for a 15-member family of Qataris of K=9 
Persian ancestry, and a diverse panel of n=16 Qatari exomes. 
In order to quantify the impact of using GRCh37 versus QTRG3 as a reference on the 
quality of variant genotypes, a single Qatari was quadruple-sequenced (2 exomes and 2 ge-
nomes) and mapped to both references. After the analysis was completed, a total of n=8 callsets 
were produced and compared. The focus of the analysis was sites covered with at least 12* depth 
in all four platforms. Within these intervals, no discordant genotypes were observed within the 
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four GRCh37 calls nor within the QTRG3 calls. The coverage depth was 1* to 2* higher at vari-
ant sites in the genomes, while coverage depth was 4* to 6* lower at variant sites in the exomes 
(Supplemental Table VI). A 10.3% reduction of variants was observed, lower than expected giv-
en that 42.28% of the GRCh37 variants are MAAs incorporated into the reference.  
 In order to quantify the impact of using GRCh37 versus QTRG3 on sensitivity for vari-
ants beyond those modified in the reference, Illumina paired-end 100 bp genome sequencing 
reads for n=15 Qataris from a family of Persian ancestry were mapped to both GRCh37 and 
QTRG3. An average of 23% (7*) depth improvement was observed when using QTRG3 (Sup-
plemental Table VII). The number of variants observed per genome was reduced on average 
n=756,671 (16%), however this was on average 25% lower than expected, based on an average 
of 41% modified sites in each genome (Supplemental Table VII).   
Given the diversity of the Qatari population, use of the QTRG reference may not provide 
the same benefit for all ancestries. In order to quantify ancestry-specific differences in depth and 
variant sensitivity, genome analysis using both GRCh37 and QTRG3 was conducted for a di-
verse panel of n=16 Qatari exomes. In contrast to the genome, across all ancestries a reduction of 
variants (up to 76%) was observed to be in excess of the expected (up to 42%, based on modified 
sites). A significant difference in the reduction was observed between Qataris of Sub-Saharan 
African ancestry and Qataris of Bedouin or Arab ancestry (one-tailed t-test p value < 0.01) (Sup-
plemental Table VIII). 
Liftover of Mendelian Disease Variants in Qataris 
 A major challenge for use of the QTRG3 reference that incorporates MAA SNPs and in-
dels is the migration of variant positions due to indels. The position of known variants and of 
genes is different in QTRG3 than in GRCh37. Hence, a major obstacle to use of QTRG3 in pre-
cision medicine studies is the lack of genome interpretation databases on QTRG3 coordinates. A 
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similar issue arises in genomics when a novel assembly of the human reference genome is pro-
duced, the translation of coordinates from one assembly to another is known as a “liftover”26. 
There is an established methods to accomplish this task, involving pairwise sequence alignment 
of pairs of chromosomes, such as GRCh37 Chr20 and QTRG3 Chr20, and then using the align-
ment the coordinates for a list of sites on GRCh37 Chr20 are “lifted over” to QTRG3 Chr20 co-
ordinates.  
 Variants were annotated using SNPEFF32 (Supplemental Table IX.), and potentially dele-
terious SNPs in coding genes were then grouped into three categories. Out of n=20,864,277 
SNPs, a total of n=155,571 are potentially pathogenic protein coding SNPs (Category 3), includ-
ing n=50,757 in genes linked to a phenotype (Category 2) and n=2,152 of these that are variants 
with known links to a phenotype (Category 1; Table II). Based on ACMG recommendations10, 
only the n=1,020 (999 + 21) Category 1 at minor allele frequency below 5% (rare) are retained 
for further consideration (Table II). The rare Category 1 variants were further filtered to exclude 
n=200 singletons (single alleles in the population), which are enriched for false positives (Sup-
plemental Figure 3). The literature for the remaining variants was reviewed, and n=122 variants 
linked to a phenotype that can clearly be defined as a Mendelian (dominant, recessive, x-linked) 
disease are presented in Supplemental Table X. By using the liftover method, the QTRG3 coor-
dinates for these pathogenic variants was ascertained (Supplemental Table X). 
Discussion 
This study presents a set of publicly available bioinformatics tools and resources for ge-
nome interpretation studies in Qatar and closely related MENA populations. Over 1000 Qataris 
were sequenced to produce this resource, effectively sampling nearly 0.4% of the indigenous 
population of Qatar. Of 26 million SNPs and indels observed in the autosomes, sex chromo-
somes, and mitochondrial DNA, over 9% were in fact the major allele in Qatar.  Using the com-
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plete catalog of variants, a reference genome custom tailored to disease research in the Qatari 
population was constructed, named here the Qatari Reference Genome (QTRG).   
The value of utilizing the QTRG vis-a-vis the standard reference genome GRCh37 was 
demonstrated through improved read depth and variant sensitivity. Use of this reference in Qatar 
will lead to higher quality interpretation for both individual genomes and Mendelian disease 
studies. In order to facilitate Mendelian disease research using the QTRG, a catalog of known 
pathogenic mutations in Qatar was compiled, with genomic coordinates on both the GRCh37 and 
QTRG included. 
 Although prior studies have constructed reference genomes tailored to distinct ances-
tries8, this is the first such study that incorporates both SNPs and indels into the reference, and 
solves crisis of genome interpretation that would ensue without liftover of genomic coordinates 
for known variants. While in the near future de novo assembly of personal genomes could be-
come routine33, the reference genome is expected to remain useful for comparisons across a large 
sample of genomes, and for comparison to public databases.  As expressed by the version infor-
mation for QTRG (version 1, 2 and 3), future versions of the Qatari Reference Genome are there-
fore planned for release, based on inclusion of major alleles for a broader spectrum of genetic 
variation (such as CNVs, genome rearrangements, and short tandem repeats), and ongoing sam-
pling and sequencing of a larger representation both within Qatar and in the MENA region.  
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 Table I. Individual Variant Discovery in 1005 Unrelated Qatari1 
Statistic 
Genome (n=88) 51 Mb Exome (n=853) 38 Mb Exome (n=64) 
Individual Autosomes ChrX ChrY MtDNA Individual Autosomes ChrX ChrY Individual Autosomes ChrX ChrY 
Variant sites 4,045,064 3,893,076 151,017 937 34 15,382 15,069 312 1 13,839 13,538 300 1 
Novel variant sites 96,774 77,366 19,359 42 7 159 152 7 0 96 91 5 0 
Novel variant rate 2.39% 1.99% 12.82% 4.48% 20.59% 1.03% 0.99% 2.24% 0.00% 0.69% 0.67% 1.67% 0.00% 
Alternate alleles 5,510,301 5,311,794 196,565 1,874 68 21,046 20,613 431 2 19,116 18,709 405 2 
Novel alternate alleles 98,792 78,916 19,778 84 14 160 153 7 0 97 92 5 0 
Novel allele rate 1.79% 1.49% 10.06% 4.48% 20.59% 0.76% 0.74% 1.62% 0.00% 0.50%  0.49% 1.23% 0.00% 
Heterozygous sites 2,594,268 2,489,084 105,184 - - 9,759 9,564 195 - 8,897 8,698 199 - 
Novel heterozygous sites 94,762 75,772 18,990 - - 157 150 7 - 94 89 5 - 
Novel heterozygous rate 3.65% 3.04% 18.05% - - 1.61% 1.57% 3.59%   - 1.06% 1.02% 2.51% - 
Mean depth at variant site 41 41 40 20 250 63 64 69 42 64 64 74 27 
Mean depth at novel variant site 41 41 39 20 250 59 60 60 47 63 63 76 - 
Transition:transversion ratio 2.03 2.03 1.78 1.51 33.00 3.18 3.18 2.77 - 3.25 3.26 2.67 - 
Novel transition:transversion ratio 1.33 1.35 1.09 1.63 - 0.77 0.77 0.75 - 1.58 1.56 1.50 - 
1 Shown is a summary of the average number of variants observed per individual, identified in 917 unrelated Qatari exomes and 88 unrelated Qatari genomes. Variants were genotyped 
separately for autosomes, X in males, X in females, Y in males, and mtDNA. 99.8% of X variants in males were also observed in females, hence summary statistics are based on female 
chromosomes. Shown is the average per individual of number of variant sites, number of variant alleles, the transition-to-transversion ratio (Ts:Tv) of variants, and the % not in dbSNP 
(novel). 
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Table II. Variants in Qatar, Stratified by Allele Frequency and Potential for Pathogenicity1 
Category 
All variant alleles 
(GRCh37) 
Major reference allele (MRA) Major alternate allele (MAA) 
Rare alternate allele 
(< 5% alternate allele 
frequency) 
Common alternate al-
lele  
(5% to 50% alternate 
allele frequency) 
Common reference al-
lele  
(50% to 95% alternate 
allele frequency) 
Rare reference allele  
(95% to 100% alter-
nate allele frequency) 
Unobserved reference 
allele 
(100% alternate allele 
frequency) 
n % n % n % n % n % n % 
All SNPs 20,864,277 100.00 12,948,368 62.06 5,938,490 28.46 1,693,649 8.12 195,466 0.94 88,303 0.42 
3- Potentially pathogenic  155,571 0.75 124,947 0.60 23,282 0.11 5,957 0.03 956 <0.01 428 <0.01 
2 - In gene linked to phenotype  50,757 0.24 40,894 0.20 7,445 0.04 2,002 0.01 290 <0.01 125 <0.01 
1 - Variant with known link 2,152 0.01 999 <0.01 876 <0.01 253 <0.01 21 <0.01 2 <0.01 
1 The major allele variants are modified in the QTRG genome, such that all reported variants are the minor allele. A total of 230,395 potentially deleterious SNPs in the 917 exomes 
and 88 genomes were computationally categorized with respect to allele frequency and databases of genes and variants with reported links to a phenotype. Variants were assigned to 
genes and their function was predicted with respect to ENSEMBL34 gene models using SNPEFF32, and potentially deleterious coding SNPs (nonsynonymous, splice donor site, 
splice acceptor site, stop gain, start loss) variants were extracted for further analysis. A database that combines OMIM35, HGMD36, GWAS37, PharmGKB38, Human Phenotype On-
tology39, and ClinVar40 was compiled, where these annotations were used to divide the potentially deleterious variants into three categories, variant and gene linked to a phenotype 
(Category 1), gene but not variant linked to a phenotype (Category 2), and neither variant nor gene linked to a phenotype (Category 3). The totals for each category are shown in the 
left-most columns, including number and percentage. These variants were then sub-classified into two major (major reference allele, major alternate allele) and 5 minor categories 
based on variant allele frequency in Qatar rare alternate allele (up to 5% variant allele frequency), common alternate allele (between 5% and 50% allele frequency), common refer-
ence allele (from 50% to 95% alternate allele frequency), rare reference allele (from 95% to 100% alternate allele frequency), unobserved reference allele (100% allele frequency). 
The major alternate alleles (MAA) are modified in the Qatar Reference Genome (QTRG).  
 
  
 Figure Legends 
Figure 1. Differences in mapped read depth across reference genomes. In order to select the op-
timal reference for analysis of Qatari genomes and exomes, the mapped read depth was com-
pared between GRCh37 and three alternative reference genomes based on major alternate alleles 
(MAA) observed in n=1005 Qatari. Illumina paired-end 100 bp reads for 37* genome sequenc-
ing of a female Qatari were mapped using BWA to GRCh37, QTRG1, QTRG2, and QTRG3 ref-
erence genomes. The differences between the three Qatari references is that QTRG1 incorporates 
MAA SNPs, QTRG2 incorporates MAA indels, and QTRG3 incorporates both MAA SNPs and 
MAA indels. The depth of coverage was measured at A. across the genome and B. at MAA sites 
modified in the QTRG. 
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Supplemental Methods 
Inclusion Criteria 
 In order to maximize the accuracy of Qatari ancestry inference, both Qataris and non-Qa-
tari Non-Qataris living in Qatar were selected for sequencing. As selection criteria for Qataris, 
subjects were required to be third generation Qataris where all four grandparents were Qatari cit-
izens born in Qatar, as assessed by questionnaires. Recent immigrants or residents of Qatar who 
traced their recent ancestry to other geographic regions were classified as Non-Qataris. DNA was 
extracted from blood using the QIAamp DNA Blood Maxi Kit (Qiagen Sciences Inc., German-
town, MD). 
 DNA samples were collected for a total of 1,376 unique individuals. Samples included in 
this study were obtained from two separate studies, the first being a study of diabetes in unre-
lated Qataris (1,084), and the second being a study of Mendelian disorders in Qatari and Non-
Qatari families living in Qatar (292).  
Ancestry Informative Marker Panel Genotyping 
 An initial estimate of the ancestry of each Qatari was conducted on all 3-generation Qata-
ris. Based on prior studies of Affymetrix 5.01,2 and exome sequencing1,3,4 of Qataris, most Qata-
ris can be placed into one of three ancestry subpopulations: Bedouin (Q1), Persian/South Asian 
(Q2) and African (Q3)1,4. An estimate of the relative proportions of tripartite ancestry was also 
estimated in each Qatari based on genotypes for a panel of 48 ancestry-informative SNPs4 ascer-
tained using the TaqMan platform (Life Technologies, Carlsbad, CA), followed by 
STRUCTURE5 analysis with k=3, where individuals with at least 65% ancestry in one of three 
clusters were classified as “low admixture” Qataris. Qataris were recruited for genetic studies at 
Hamad Medical Corporation clinics, and consenting volunteers were initially genotyped on the 
48-SNP ancestry panel. Individuals with a high proportion of ancestry in one of three clusters 
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were prioritized for sequencing. DNA was extracted from blood using the QIAamp DNA Blood 
Maxi Kit (Qiagen Sciences, Germantown, MD). 
Genome Sequencing 
 In order to characterize the spectrum of Qatari genetic variation, 108 Qataris were se-
quenced to a median depth of 37x on the Illumina platform. Next-generation sequencing libraries 
were generated using the Illumina TruSeq protocol, and sequencing was conducted at the Illu-
mina FastTrack Services sequencing facility using the HiSeq 25006. Sufficient paired-end 100 bp 
reads were generated in order to produce a median of 112 GB of sequence data passing filters 
and aligned to the hg19 human reference genome with a median insert size of 301 bp, where at 
least 85% of bases ≥Q30, passed filtering steps and were aligned. Among non-N bases in the ref-
erence genome, at least 98% were covered by at least one base in all 108 genomes. Reads were 
realigned to the 1000 Genomes Project version of the GRCh37 human reference genome using 
BWA 0.5.97 (maximum insert size 3 kb), and mapped reads were prepared for variant calling us-
ing GATK Best Practices8, including PCR duplicate removal using SAMtools9, producing an av-
erage of 37x depth in autosomal chromosomes, with a mean of 98% of mappable sites covered 
per genome. SNP genotypes for all 108 genomes were simultaneously called using GATK10. In 
addition, short indel (<300 bp) calls were produced using the CASAVA 1.9 pipeline by Illumina.  
Exome Sequencing 
 Exome sequence data was produced for 1,268 Qataris. In addition, 53 technical replicates 
were produced, a total of 1,321 exomes sequenced and analyzed, where the entire sample in-
cluded 1,053 unique Qataris and 215 unique Non-Qataris. A total of 1,221 exomes were se-
quenced by the New York Genome Center (NYGC), an additional 100 Qatari were sequenced at 
Beijing Genomics Institute (BGI)4. The NYGC exomes were produced using Agilent SureSelect 
Human All Exome 51 Mb targets, and are hearafter referred to as “Exome51Mb”, while the BGI 
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exomes were produced using Agilent SureSelect Human All Exome 38 Mb targets, hereafter re-
ferred to as “Exome38Mb”. 
 The Exome51Mb batch was produced using standard methods. Exome DNA enrichment 
was performed using Agilent SureSelect Human All Exon Kit V5 (Agilent Technologies, Santa 
Clara, CA) hybrid capture targets for 51 Mb of coding regions, with sequencing on the Illumina 
HiSeq 2500 platform6. Reads were mapped to GRCh37 using BWA v0.5.97, mean coverage 
depth was verified to be greater than 30x for all autosomal chromosomes in all samples. Quality 
filtering of mapped reads was conducted using the GATK Best Practices workflow8, including 
realignment across known indels, recalibration of base quality scores, and removal of duplicate 
reads.   
Technical Replicates 
 Technical replicates in the study included 5 sequenced in triplicate (genome, Ex-
ome38Mb, Exome51Mb) and 43 that were sequenced on two platforms, including 26 genome 
and Exome38Mb (31 total, including the 5 triplicates), 4 sequenced genomes Exome51Mb (9 to-
tal, including the 5 triplicates), 2 sequenced in both Exome51Mb and Exome38Mb batches (7 to-
tal), and 11 sequenced twice in the Exome51Mb batch. The genotypes for these technical repli-
cates were compared to assess overall reproducibility across sequencing platforms. The genome 
of the triplicate (a Qatari female) was subsequently sequenced on a fourth platform (Illumina 
HiSeq X), in order to have one quadruple-sequenced Qatari to use as a benchmark for analysis.  
Integrated Analysis of Exome and Genome Samples 
 In order to conduct analysis of population structure and relatedness on the maximum 
number of samples, genotype data from the 108 genomes was integrated with exome sequence 
data for 1,268 Qataris. Including the technical replicates, a call set for all 1,429 samples was pro-
duced by simultaneous genotyping using the GATK UnifiedGenotyper algorithm10. Genotype-
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ready BAM alignment files were prepared as described above for genome, Exome51Mb, and Ex-
ome38Mb samples. Genotype calling was limited to sites in the Agilent SureSelect 38Mb targets 
that overlap CCDS build 15 coding exons11. Variants observed in at least one sample with Q30 
or higher were reported. All bi-allelic SNPs genotyped successfully in at least 80% of samples 
were kept for further analysis. In order to facilitate downstream analysis, variant VCF files were 
converted to PLINK12 format using PLINK213. 
Optimization of Batch-Specific Genotype Filters 
Integration of data from three distinct batches of sequence data produced at three distinct 
sequencing centers on three distinct sequencing library preparation kits and three different ver-
sions of the Illumina sequencer introduces a number of variables that could potentially result in-
batch effects in the variant calls. Novel variants, defined as those not present in dbSNP (build 
146 being the latest at the time of writing), singletons (single alleles observed in only one indi-
vidual in the population sample), and genotypes with low sequencing depth are typically en-
riched for sequencing errors and batch artifacts14. Hence, one way to control for batch effects is 
to filter variants below a threshold depth d and threshold variant allele count v, such that the 
mean novel SNP rate is consistent across batches within genomic intervals covered by the inter-
section of all batches. In order to optimize d and v, two approaches were followed. First, the 
novel SNP rate for a range of d and v thresholds were calculated in each batch, and batch-spe-
cific d and v that produced the highest possible consistent novel SNP rate was selected and ap-
plied to each call set. Second, the impact of the selected batch-specific filters d and v were ap-
plied to the quadruple-sequenced Qatari, and the proportion of batch-specific variants (defined as 
variants observed in only one of the four batches in the quadruple-sequenced Qatari) was com-
pared before and after application of filters. The proportion of batch-specific variants was calcu-
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lated for both all variants and novel variants, with the aim of controlling the batch-specific vari-
ants at below 5%.  
A major concern when applying genotype filters is the risk of reducing sensitivity for 
known and novel variants. In order to confirm that overly-stringent filtering was applied, the im-
pact of the selected filters on sensitivity and novel SNP rate was assessed across a range of 
depths for the quadruple-sequenced Qatari, in order to ensure that the number of variants ob-
served within CCDS coding exons (within the Exome38Mb target intervals) was in the range of 
published benchmarks of per-exome variant counts15, and that excess novel SNP rates were 
avoided. 
Population Structure 
 In order to quantify admixture in 1,161 Qataris and 215 Non-Qataris living in Qatar, the 
integrated SNP genotypes of 1376 individuals within Agilent SureSelect 38 Mb targets were in-
tegrated with 4,235 genomes from public databases. The public databases included 1,862 from 
Human Origins (HumOr), 1,028 from 1000 Genomes Phase 1 not in HumOr (1000Gp1), and 
1,345 from 1000 Genomes Phase 3 not in HumOr nor 1000Gp1 (1000Gp3).  The integrated vari-
ant dataset included 5,611 SNPs segregating in all datasets (Qatar Genomes, Qatar Exomes, Hu-
mOr, 1000Gp1, 1000Gp3) after filtering to exclude SNPs with more than 20% missing geno-
types, SNPs with Hardy Weinberg equilibrium p value < 1x10-6 (as calculated using PLINK2), 
and SNPs removed by linkage disequilibrium pruning (conducted using the PLINK2 –indep-
pairwise function in a sliding window of 1000 SNPs, step size 25 SNPs, and exclusion of SNPs 
with r2 > 0.1). Inference of ancestry was conducted using ADMIXTURE16 for the 5,611 individ-
uals. Ancestry proportion inference was conducted using K=12, based on lowest cross-validation 
error in a prior study17. For each individual, ADMIXTURE outputs the proportion of ancestry in 
each ancestral population (K). Each individual was assigned to the ancestral population with the 
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largest proportion in his or her genome.  
Relatedness 
 Given the high rate of consanguineous marriage in Qatar18, and the inclusion of complete 
families in our study, the potential over-sampling of relatives and families in sample of the popu-
lation is high. In order to avoid over-sampling or alleles from relatives, and produce allele fre-
quency estimates for the general Qatari population, the pairwise relatedness between 1,376 sam-
ples (including Qataris and Non-Qataris living in Qatar, after exclusion of technical replicates) 
was calculated using KING19, and 1st/2nd degree relatives were excluded. Genotypes used for 
comparison were limited to CCDS coding intervals covered in the intersection of the three se-
quencing batches (n=108 genome, n=67 Exome38Mb, and n=1201 Exome51Mb). Given the 
high level of inbreeding in the Qatari population18, and the use of coding variant data for the 
analysis, the pairwise relatedness estimates of KING and related software are expected to over-
estimate relatedness19-21, such that assessment of 1st/2nd degree relatedness is expected to be a lib-
eral and therefore over-assessment of relatedness in the sample. Using this liberal cutoff, a total 
of 1005 unrelated Qataris (n=88 genome, n=64 Exome38Mb, and n=853 Exome51Mb) were 
identified, resulting in the exclusion of 156 1st/2nd degree Qatari relatives. 
Construction of the Qatari Reference Genome (QTRG) 
 Total variants were counted in each chromosome of the n=88 unrelated Qatari genomes 
and n=917 unrelated Qatari exomes, and an aggregate variant list was compiled. Variant allele 
frequency was calculated using PLINK212 and VCFtools22. Novel variants (defined as not pre-
sent in dbSNP build 146) were quantified in both individual and aggregate sets, as was the Ts:tv 
ratio (measured using VCFtools22).Variants in Qatar were divided into 2 categories based on 
which allele is the major allele, subsequently described as major reference alleles (MRA) and 
major alternate alleles (MAA)  
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 Three versions of the Qatar Reference Genome were produced. In order to produce an in-
itial version of the Qatari Reference Genome (referred to as “QTRG1”), the standard reference 
genome (GRCh37) was modified at all sites where the variant allele in Qatar is the major allele 
in Qatar, in this case including all MAA SNPs. The modifications to the GRCh37 FASTA23 file 
was conducted using VCFtools22, which takes the reference genome and a VCF file with the ma-
jor allele variants as inputs, and outputs a modified FASTA file. QTRG1 was prepared for use in 
analysis of human genomes and exomes by creation of indexed versions of the reference using 
SAMtools9, Picard7,24, and BWA7. A second version of the Qatar Reference Genome (QTRG2) 
was produced by including all MAA indels. A third version of the Qatar Reference Genome 
(QTRG3) was produced by including the MAA SNPs and MAA indels. 
Assessment of QTRG vs GRCh37 on “n+1” Qatari  
 The value of the QTR1 population-specific reference genome for assessing major and mi-
nor allele variants was demonstrated by genome interpretation of the next Qatari sequenced, re-
ferred to the “n+1” genome, defined as the “next” genome sequenced and analyzed using data 
from the panel of n=1005 genomes analyzed thus far. The n+1 analysis was conducted by taking 
the sequence data for an individual genome, and processing it twice using the same GATK Best 
Practices Workflow8, with the only difference being the reference genome used. Three experi-
ments were conducted in order to assess the value of using QTRG. First, genome sequence data 
for the quadruple-sequenced Qatari was mapped to four references (including GRCh37, QTRG1, 
QTRG2, and QTRG3), and differences in mapped read depth at both modified and unmodified 
sites was compared. The reference with the greatest mapped read depth (in this case QTRG3) 
was selected for the two other experiments. Second, a family of 15 genomes sequenced at 37x 
depth using paired-end Illumina 100bp sequencing was analyzed using the GATK Best Practices 
Workflow8 twice, with the only change being the reference genome used (GRCh37 or QTRG3). 
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The depth and number of variants was compared between the two references for each individual. 
In addition, in order to assess the impact of using the reference beyond modified sites, the ob-
served reduction in number of variants was compared to the expected number, where the  ex-
pected reduction is the number of number of “flipped” variants (variants incorporated into the 
QTRG3 reference) present in the individual genome. The difference across the 15 genomes was 
tested for significance using a 2-df Chi-squared test. Third, the analysis was repeated on a di-
verse panel of n=16 Qatari exomes, and differences in the increased depth and reduced variant 
count was compared across populations with a one-tailed t-test. 
Gene and Variant Annotation Liftover 
 A major issue for utilizing the QTRG3 reference genome in n+1 genome interpretation is 
the need to update the positions of known genes and variants. In genomics this is known as a 
“liftover”, an analysis that is conducted each time a new version of the human reference genome 
assembly is produced. In order to assess the feasibility QTRG3 for genome interpretation, a lifto-
ver analysis was conducted for known pathogenic variants observed in filtered call set for the 
n=1005 unrelated Qatari. The variants with respect to GRCh37 were annotated, and then the var-
iant coordinates were “lifted over” to QTRG3 coordinates. The liftover process has two steps, 
first each chromosome of GRCh37 and QTRG3 are pairwise aligned using ProgressiveCactus25. 
Then, using the pairwise global alignment of the two chromosomes, a list GRCh37 coordinates 
are converted to QTRG3 coordinates using HalTools26 Given that the SNPs lifted over are pre-
sent in dbSNP, the liftover success could be assessed using the dbSNP flanking sequenced for 
each SNP, which can be aligned to QTRG3 in order to identify a precise location using 
MUMer27.   
Variant Functional Interpretation 
 Functional interpretation was conducted for the 26 million SNPs and indels identified in 
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Qatar using a combination of automated and manual algorithms. The automated curation con-
sisted of identifying potentially deleterious coding variants, annotation and subdivision of the po-
tentially deleterious variants based on presence or absence of the variants and/or affected genes 
in databases of variants and genes previously linked to phenotypes, followed by further subdivi-
sion based on variant allele frequency in Qatar.  
 Variants were assigned to genes in the ENSEMBL database build 7528 using SnpEff 
4.129. In cases where multiple alternative transcripts overlap with distinct potential functions, the 
most severely deleterious function was reported, based on a prioritization hierarchy described in 
the annotation tool manual29. SnpEff classifies variant (SNP and indel) impact into three catego-
ries “high”, “moderate”, “low”, or “modifier”, where loss of function (LoF) variants are classi-
fied as high impact, nonsynonymous variants are classified as moderate impact, the remaining 
coding variants are classified as low impact, and most non-coding variants are classified as mod-
ifier impact. The high impact and moderate impact variants are considered potentially deleteri-
ous, and further classified with respect to databases of variant function and allele frequency. A 
known or potential link to a phenotype was determined using a database that combines Online 
Mendelian Inheritance in Man (OMIM)30, the Human Gene Mutation Database (HGMD)31, 
GWAS Catalog (GWAS)32, and Pharmacogenomics Knowledgebase (PharmGKB)32,33, Clin-
Var34, and Human Phenotype Ontology (HPO)35. While the HGMD, GWAS, PharmGKB, and 
ClinVar databases provide annotation for variants, the OMIM database also provides information 
for genes and phenotypes, and HPO provides additional detail on the OMIM phenotypes (such as 
recessive/dominant classification). Qatari variants linked to a phenotype in the combined data-
base of genes and variants linked to disease were identified based on the gene symbol containing 
the variant or the dbSNP rsID of the variant. The workflow for automated annotation starts with 
a VCF of all variants observed in the n=88 unrelated Qatari genomes or n=917 unrelated Qatari 
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exomes. Each variant is assigned a function by SnpEff, with additional details provided for cod-
ing SNPs, such as transcript and polypeptide position and amino acid changes in HGVS format36. 
The variants were also assigned dbSNP 146 rsIDs, which were used to lookup the variant in the 
databases.  
 Potentially deleterious variants (high or moderate impact) are then queried against a data-
base of variants linked to disease. The database includes the rsID, affected gene, phenotype 
linked to the variant, details of the phenotype, MIM ID of the gene and phenotype if available, 
and reference to the source database. This query produces the first group of variants (Cate-
gory 1), where the variant (and the gene) are previously linked to a phenotype in one or more of 
the databases. The variants not present in the database are then queried against a list of all genes 
in the database, in order to produce the second group of variants (Category 2), variants not previ-
ously linked to a phenotype in genes previously linked to a phenotype. The remaining variants 
were placed a third group (Category 3), consisting of variants not linked to a phenotype in genes 
not previously linked to a phenotype.  
 The functional analysis was further stratified based on allele frequency. Each of the four 
categories of variants (all, Category 1, Category 2, Category 3) were stratified into 3 major 
groups (all, major reference allele, major alternate allele), and 5 minor groups (major reference 
allele / rare alternate allele, major reference allele / common alternate allele, major alternate al-
leles / common reference allele, major alternate allele / rare reference allele, major alternate al-
lele / unobserved reference allele), where the threshold for “rare” alleles is 5% minor allele fre-
quency and the threshold for “major” alleles is 50% major/minor allele frequency. 
Curated List of Known Pathogenic Variants for Mendelian Disorders in Qatar 
 The set of Category 1 variants were filtered using a set of strict automated and manual 
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curation steps, in order to produce a list of potential disease causing variants of interest for fur-
ther study and potentially of value for an expanded genetic screening panel in Qatar4. The total 
set of potentially deleterious variants were filtered based on prevalence of the variant as well as 
the quality of literature linking the variant to a disease phenotype. The American College of 
Medical Genetics (ACMG) recommends excluding variants at prevalence above 5% minor allele 
frequency, in order to enrich for pathogenic variants37. Such a filter is consistent with a basic 
principle of evolutionary biology states that the prevalence of an allele in the population is ex-
pected to be inversely proportional to its pathogenic severity38, with the most severely patho-
genic variants expected to be rare. In addition, in order to minimize false positives, variants that 
were observed in at least two Qataris were keep for further consideration. 
 The Category 1 variants include all variants linked to a phenotype, including anthropo-
morphic traits (eye, hair color), GWAS hits, pharmacogenomics SNPs, and variants linked to 
Mendelian disorders, across the allele frequency spectrum. For the purpose of improving preci-
sion medicine in Qatar with respect to Mendelian disease variant screening, the focus of manual 
curation was on variants linked to Mendelian disorders. In order to identify a high-confidence set 
of known pathogenic variants, the database records and literature of the initial set of Category 1 
variants linked to phenotypes were manually inspected. The initial criteria for extracting variants 
for manual curation were based on the phenotype (Mendelian or not). Variants were excluded 
from the manual curation list based on phenotype not listed as “recessive” or “dominant” Mende-
lian disorder in OMIM30 and HPO39. For the remaining variants, a manual curation process was 
implemented to identify a subset of high-confidence pathogenic variants for precision medicine 
disease screening in Qatar. First, the entry for each variant on the OMIM webpage was evaluated 
to determine the strength of evidence supporting this variant’s pathogenicity in the reported dis-
ease. For this step, the entry was scrutinized by a geneticist blinded to variant-specific metrics 
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(observed homozygotes/heterozygotes), in each instance reporting inheritance mode of the dis-
ease documented for this variant (as RECESSIVE, DOMINANT, SEMIDOMINANT, DIGENIC 
or MODIFIER) along with relevant severity and onset information (as MILD, LATE-ONSET, 
INCOMPLETE/REDUCED PENTRANCE, or PHARMACOGENETIC). Where any of this in-
formation was missing from the OMIM page, the primary literature was investigated in detail by 
reviewing the initial publication in which the subject with disease was initially described, as well 
as any subsequent publication that supported or overturned the pathogenicity. The final criteria 
for exclusion was variants associated with but not causal for a disease (conferring odds of risk of 
disease), pharmacogenetic variants (requiring a challenge by a drug for a phenotype), or variants 
that were reclassified in more recent studies as polymorphisms or variants of unknown signifi-
cance.  
Supplemental Table I. Batch-specific variant filters for call set integration of 108 genomes and 1268 exomes 1 
Nickname Genome Exome 38 Mb Exome 51 Mb 
Sequencing breadth Whole genome Whole exome Whole exome 
Sequencing year 2012 2010 2014 
Enrichment platform N/A SureSelect 38 Mb SureSelect 51 Mb 
Sequencing platform Illumina HiSeq 2500 Illumina HiSeq 2000 Illumina HiSeq 2500 
Sample size 108 67 1201 
Filters 
   
Minimum depth 12 12 10 
Minimum allele count  1 1 2 
Mean depth 38 70 70 
Novel variants (% not in dbSNP 146) 0.73% 0.72% 0.72% 
Autosomal variant summary All Novel All Novel All Novel 
Variant alleles 19,355 104 18,537 100 19,229 103 
Variant sites 14,107 103 13,682 98 14,064 102 
Reference homozygotes 287,672 62,601 268,401 58,600 161,239 19,421 
Heterozygotes 8,860 102 8,826 97 8,898 101 
Variant homozygotes 5,247 1 4,856 1 5,166 1 
Homozygotes 292,919 62,603 273,257 58,602 166,405 19,422 
1. In order to produce an integrated variant call set based on sequence data from three different batches (1 genome, 2 exome), batch-specific variant filters were ap-
plied, such that the novel SNP rate was consistent across platforms when inspecting genomic intervals covered by all platforms. Genotypes generated using GATK 
best practices were produced for autosomal coding exons covered by Agilent SureSelect 38 Mb targets, the most restricted platform used (with respect to breadth of 
genome sampled), and further limited to known coding exons present in the CCDS database (which is an intersection of RefSeq, ENSEMBL, and UCSC defined 
genes). From the initial call set, sites with a PHRED-scaled genotype quality above 30 were further filtered using a range of minimum depth and minimum allele 
count, and compared with respect to novel SNP rate (defined as the percentage of variant sites not previously observed in dbSNP build 146). The combinations were 
sorted by increasing novel SNP rate, and batch-specific parameters were selected such that (a) both exome platform novel SNP rates are lower than the genome 
novel SNP rate, the genome novel SNP rate is as close as possible to the exome novel SNP rate, and the lowest SNP rate is as high as possible. Based on analysis of 
a quadruple-sequenced Qatari, the batch-specific novel variant rate for these parameters is below 5%. Shown are the sequencing parameters, calibration parameters, 
and autosomal variant summary for each platform. Sequencing parameters include a name for each platform (including the sequencing center), the sequencing 
breadth (exome or genome), the year the sequencing was completed, the target enrichment platform, the sequencing platform. The Calibration parameters include the 
minimum depth, minimum allele count, mean variant depth, and percentage of novel variants (not in dbSNP 146) for the selected optimal batch-specific filters. The 
autosomal variant summary presents for all and for novel SNPs the average result per individual for the selected calibration parameters, including number of variant 
alleles, variant sites, reference homozygous genotypes, heterozygous genotypes, variant homozygous genotypes, and total homozygotes. 
Supplemental Table II. Populations included in ADMIXTURE and PCA analysis1 
 
Study Region Population n 
1000Gp1 AFR ASW 61 
1000Gp1 AFR LWK 95 
1000Gp1 AFR YRI 57 
1000Gp1 AMR CLM 60 
1000Gp1 AMR MXL 66 
1000Gp1 AMR PUR 55 
1000Gp1 EAS CHB 97 
1000Gp1 EAS CHS 100 
1000Gp1 EAS JPT 89 
1000Gp1 EUR CEU 85 
1000Gp1 EUR FIN 86 
1000Gp1 EUR GBR 76 
1000Gp1 EUR IBS 3 
1000Gp1 EUR TSI 98 
1000Gp3 AMR ACB 96 
1000Gp3 AMR ASW 7 
1000Gp3 AMR CLM 36 
1000Gp3 AMR MXL 5 
1000Gp3 AMR PEL 85 
1000Gp3 AMR PUR 49 
1000Gp3 EASN CDX 93 
1000Gp3 EASN CHB 8 
1000Gp3 EASN CHS 13 
1000Gp3 EASN JPT 15 
1000Gp3 EASN KHV 91 
1000Gp3 EUR CEU 15 
1000Gp3 EUR FIN 10 
1000Gp3 EUR GBR 9 
1000Gp3 EUR IBS 44 
1000Gp3 EUR TSI 11 
1000Gp3 SASN BEB 79 
1000Gp3 SASN GIH 86 
1000Gp3 SASN ITU 102 
1000Gp3 SASN PJL 88 
1000Gp3 SASN STU 102 
1000Gp3 WAFR ESN 91 
1000Gp3 WAFR GWD 107 
1000Gp3 WAFR LWK 12 
1000Gp3 WAFR MSL 78 
1000Gp3 WAFR YRI 13 
Non-Qatari in Qatar Exome Africa Algerian 1 
Non-Qatari in Qatar Exome Africa American/Egyptian 5 
Non-Qatari in Qatar Exome Africa Egyptian 41 
Non-Qatari in Qatar Exome Africa Eritrean 4 
Supplemental Table II. Populations included in ADMIXTURE and PCA analysis1 (cont., page 2) 
Study Region Population n 
Non-Qatari in Qatar Exome Africa Morracan 1 
Non-Qatari in Qatar Exome Africa Nigerian 2 
Non-Qatari in Qatar Exome America American 5 
Non-Qatari in Qatar Exome America Argentenian 1 
Non-Qatari in Qatar Exome East Asia Filipino 3 
Non-Qatari in Qatar Exome East Asia Nepalese 1 
Non-Qatari in Qatar Exome Middle East Arab 1 
Non-Qatari in Qatar Exome Middle East Iranian 10 
Non-Qatari in Qatar Exome Middle East Iraqi 1 
Non-Qatari in Qatar Exome Middle East Jordanian 21 
Non-Qatari in Qatar Exome Middle East Jordanian/Arab 3 
Non-Qatari in Qatar Exome Middle East Jordanian/Palestinian 1 
Non-Qatari in Qatar Exome Middle East Lebanese 4 
Non-Qatari in Qatar Exome Middle East Omani 8 
Non-Qatari in Qatar Exome Middle East Palestinian 20 
Non-Qatari in Qatar Exome Middle East Saudi 3 
Non-Qatari in Qatar Exome Middle East Sri-Lankan 1 
Non-Qatari in Qatar Exome Middle East Sudanese 16 
Non-Qatari in Qatar Exome Middle East Syrian 9 
Non-Qatari in Qatar Exome Middle East Tunisian 5 
Non-Qatari in Qatar Exome Middle East Yemeni 5 
Non-Qatari in Qatar Exome South Asia Bangladeshi 2 
Non-Qatari in Qatar Exome South Asia Indian 10 
Non-Qatari in Qatar Exome South Asia Indian/Asian 5 
Non-Qatari in Qatar Exome South Asia Pakistani 26 
Human Origins Africa AA Denver 12 
Human Origins Africa Algerian 7 
Human Origins Africa Bantu SA Herero 2 
Human Origins Africa Bantu SA Ovambo 1 
Human Origins Africa Bantu SA Pedi 1 
Human Origins Africa Bantu SA S Sotho 1 
Human Origins Africa Bantu SA Tswana 2 
Human Origins Africa Bantu SA Zulu 1 
Human Origins Africa BantuKenya 6 
Human Origins Africa BiakaPygmy 20 
Human Origins Africa Datog 3 
Human Origins Africa Esan Nigeria ESN 8 
Human Origins Africa Gambian GWD 6 
Human Origins Africa Hadza Henn 5 
Human Origins Africa Ju hoan North 5 
Human Origins Africa Khomani 11 
Human Origins Africa Kikuyu 4 
Human Origins Africa Luhya Kenya LWK 8 
Human Origins Africa Luo 8 
Human Origins Africa Mandenka 17 
Supplemental Table II. Populations included in ADMIXTURE and PCA analysis1 (cont., page 3) 
Study Region Population n 
Human Origins Africa Masai Ayodo 2 
Human Origins Africa Masai Kinyawa MKK 10 
Human Origins Africa MbutiPygmy 10 
Human Origins Africa Mende Sierra Leone MSL 8 
Human Origins Africa Mozabite 21 
Human Origins Africa Saharawi 6 
Human Origins Africa Somali 13 
Human Origins Africa Tunisian 8 
Human Origins Africa Yoruba 70 
Human Origins America Bolivian Cochabamba 1 
Human Origins America Bolivian LaPaz 3 
Human Origins America Bolivian Pando 3 
Human Origins America Karitiana 12 
Human Origins America Mayan 18 
Human Origins America Mixe 10 
Human Origins America Mixtec 10 
Human Origins America Piapoco 4 
Human Origins America Pima 14 
Human Origins America Quechua Coriell 5 
Human Origins America Surui 8 
Human Origins America Zapotec 10 
Human Origins Central Asia Siberia Aleut 7 
Human Origins Central Asia Siberia Altaian 7 
Human Origins Central Asia Siberia Chukchi 20 
Human Origins Central Asia Siberia Chukchi Reindeer 1 
Human Origins Central Asia Siberia Chukchi Sir 2 
Human Origins Central Asia Siberia Dolgan 3 
Human Origins Central Asia Siberia Eskimo Chaplin 4 
Human Origins Central Asia Siberia Eskimo Naukan 13 
Human Origins Central Asia Siberia Eskimo Sireniki 5 
Human Origins Central Asia Siberia Even 10 
Human Origins Central Asia Siberia Itelmen 6 
Human Origins Central Asia Siberia Kalmyk 10 
Human Origins Central Asia Siberia Koryak 9 
Human Origins Central Asia Siberia Kyrgyz 9 
Human Origins Central Asia Siberia Mansi 8 
Human Origins Central Asia Siberia Mongola 6 
Human Origins Central Asia Siberia Nganasan 11 
Human Origins Central Asia Siberia Selkup 10 
Human Origins Central Asia Siberia Tajik Pomiri 8 
Human Origins Central Asia Siberia Tlingit 4 
Human Origins Central Asia Siberia Tubalar 22 
Human Origins Central Asia Siberia Turkmen 7 
Human Origins Central Asia Siberia Tuvinian 10 
Human Origins Central Asia Siberia Ulchi 25 
Supplemental Table II. Populations included in ADMIXTURE and PCA analysis1 (cont., page 4) 
Study Region Population n 
Human Origins Central Asia Siberia Uzbek 10 
Human Origins Central Asia Siberia Yakut 20 
Human Origins Central Asia Siberia Yukagir Forest 5 
Human Origins Central Asia Siberia Yukagir Tundra 14 
Human Origins East Asia Ami Coriell 10 
Human Origins East Asia Atayal Coriell 9 
Human Origins East Asia Cambodian 8 
Human Origins East Asia Dai 10 
Human Origins East Asia Daur 9 
Human Origins East Asia Han 33 
Human Origins East Asia Han NChina 10 
Human Origins East Asia Hezhen 8 
Human Origins East Asia Japanese 29 
Human Origins East Asia Kinh Vietnam KHV 8 
Human Origins East Asia Korean 6 
Human Origins East Asia Lahu 8 
Human Origins East Asia Miao 10 
Human Origins East Asia Naxi 9 
Human Origins East Asia Oroqen 9 
Human Origins East Asia She 10 
Human Origins East Asia Thai 10 
Human Origins East Asia Tu 10 
Human Origins East Asia Tujia 10 
Human Origins East Asia Uygur 10 
Human Origins East Asia Xibo 7 
Human Origins East Asia Yi 10 
Human Origins Middle East BedouinA 25 
Human Origins Middle East BedouinB 19 
Human Origins Middle East Druze 39 
Human Origins Middle East Egyptian Comas 11 
Human Origins Middle East Egyptian Metspalu 7 
Human Origins Middle East Iranian 8 
Human Origins Middle East Jordanian 9 
Human Origins Middle East Lebanese 8 
Human Origins Middle East Palestinian 38 
Human Origins Middle East Saudi 8 
Human Origins Middle East Syrian 8 
Human Origins Middle East Turkish 4 
Human Origins Middle East Turkish Adana 10 
Human Origins Middle East Turkish Aydin 7 
Human Origins Middle East Turkish Balikesir 6 
Human Origins Middle East Turkish Istanbul 10 
Human Origins Middle East Turkish Kayseri 10 
Human Origins Middle East Turkish Trabzon 9 
Human Origins Middle East Yemen 6 
Supplemental Table II. Populations included in ADMIXTURE and PCA analysis1 (cont., page 5) 
Study Region Population n 
Human Origins Oceania Australian ECCAC 3 
Human Origins Oceania Bougainville 10 
Human Origins Oceania Papuan 14 
Human Origins South Asia Balochi 20 
Human Origins South Asia Bengali Bangladesh BEB 7 
Human Origins South Asia Brahui 21 
Human Origins South Asia Burusho 23 
Human Origins South Asia GujaratiA GIH 5 
Human Origins South Asia GujaratiB GIH 5 
Human Origins South Asia GujaratiC GIH 5 
Human Origins South Asia GujaratiD GIH 5 
Human Origins South Asia Hazara 14 
Human Origins South Asia Kalash 18 
Human Origins South Asia Kusunda 10 
Human Origins South Asia Makrani 20 
Human Origins South Asia Pathan 19 
Human Origins South Asia Punjabi Lahore PJL 8 
Human Origins South Asia Sindhi 18 
Human Origins West Eurasia Abkhasian 9 
Human Origins West Eurasia Adygei 17 
Human Origins West Eurasia Albanian 6 
Human Origins West Eurasia Armenian 10 
Human Origins West Eurasia Balkar 10 
Human Origins West Eurasia Basque French 20 
Human Origins West Eurasia Basque Spanish 9 
Human Origins West Eurasia Belarusian 10 
Human Origins West Eurasia Bulgarian 10 
Human Origins West Eurasia Chechen 9 
Human Origins West Eurasia Chuvash 10 
Human Origins West Eurasia Croatian 10 
Human Origins West Eurasia Cypriot 8 
Human Origins West Eurasia Czech 10 
Human Origins West Eurasia English Cornwall GBR 5 
Human Origins West Eurasia English Kent GBR 5 
Human Origins West Eurasia Estonian 10 
Human Origins West Eurasia Finnish FIN 7 
Human Origins West Eurasia French 25 
Human Origins West Eurasia French South 7 
Human Origins West Eurasia Georgian Megrels 10 
Human Origins West Eurasia Greek Comas 14 
Human Origins West Eurasia Greek Coriell 6 
Human Origins West Eurasia Hungarian Coriell 10 
Human Origins West Eurasia Hungarian Metspalu 10 
Human Origins West Eurasia Icelandic 12 
Human Origins West Eurasia Italian Bergamo 12 
Supplemental Table II. Populations included in ADMIXTURE and PCA analysis1 (cont., page 6) 
Study Region Population n 
Human Origins West Eurasia Italian EastSicilian 5 
Human Origins West Eurasia Italian South 1 
Human Origins West Eurasia Italian Tuscan 8 
Human Origins West Eurasia Italian WestSicilian 6 
Human Origins West Eurasia Kumyk 8 
Human Origins West Eurasia Lezgin 9 
Human Origins West Eurasia Lithuanian 10 
Human Origins West Eurasia Maltese 8 
Human Origins West Eurasia Mordovian 10 
Human Origins West Eurasia Nogai 9 
Human Origins West Eurasia North Ossetian 10 
Human Origins West Eurasia Norwegian 11 
Human Origins West Eurasia Orcadian 13 
Human Origins West Eurasia Russian 22 
Human Origins West Eurasia Saami WGA 1 
Human Origins West Eurasia Sardinian 27 
Human Origins West Eurasia Scottish Argyll Bute GBR 4 
Human Origins West Eurasia Spanish Andalucia IBS 4 
Human Origins West Eurasia Spanish Aragon IBS 6 
Human Origins West Eurasia Spanish Baleares IBS 4 
Human Origins West Eurasia Spanish Canarias IBS 2 
Human Origins West Eurasia Spanish Cantabria IBS 5 
Human Origins West Eurasia Spanish Castilla la Mancha IBS 5 
Human Origins West Eurasia Spanish Castilla y Leon IBS 5 
Human Origins West Eurasia Spanish Cataluna IBS 5 
Human Origins West Eurasia Spanish Extremadura IBS 5 
Human Origins West Eurasia Spanish Galicia IBS 5 
Human Origins West Eurasia Spanish Murcia IBS 4 
Human Origins West Eurasia Spanish Pais Vasco IBS 5 
Human Origins West Eurasia Spanish Valencia IBS 5 
Human Origins West Eurasia Ukrainian East 6 
Human Origins West Eurasia Ukrainian West 3 
Qatar Exome Qatar Qatari 108 
Qatar Genome Qatar Qatari 1268 
1   Shown is the sample size in the dataset used for population structure analysis, including samples from 1000 Ge-
nomes Phase 140 (1000Gp1), 1000 Genomes Phase 341 (1000Gp3), Human Origins (HumOr), Qatar Genome 
(QG), Qatar Exome (QE), and Non-Qataris in Qatar Exome (NQE). A number of samples overlap between Hu-
mOr, 1000Gp1, and 1000Gp3, in these cases firs the HumOr samples are added, followed by non-duplicate 
samples in 1000Gp3, and finally non-duplicate samples in 1000Gp3. In order to distinguish between 1000G 
and HumOr samples for the same populations, the 1000 Genomes populations are described by a 3-letter code 
(such as YRI), while HumOr samples use the full name (such as Yoruba) in Lazardis et al 2014 supplement42. 
Shown is the study, region, population, and sample size. For Qataris, the sample size is based the sequencing 
technology used (genome or exome). Regions are based on designations in Lazardis et al 2014 (Africa, Amer-
ica, East Asia, Middle East, Qatar, South Asia, Central Asia / Siberia, Oceania, West Eurasia) and the 1000 Ge-
nomes website (AFR, AMR, EAS, EUR, EASN, SASN, WAFR), where 3-letter codes are used for Phase 1 and 
4-letter codes are used for Phase 3. 
 
Supplemental Table III. Population structure analysis1 
  K (ADMIXTURE K=12) 
Study n 1 2 3 4 5 6 7 8 9 10 11 12 
Inferred origin  
Euro-
pean 
East 
Asian 
Siberian 
 
South 
Asian Bedouin  
African  
Pygmy Oceanian Arab Persian 
Sub-Saharan  
African American 
Central 
Asian 
Qatar Genome 108 0 0 0 4 48 0 0 20 19 17 0 0 
Qatar Exome 1053 5 0 0 78 518 1 0 216 175 60 0 0 
 in Qatar Exome 215 11 2 0 49 35 2 0 9 94 13 0 0 
Human Origins 1862 418 195 103 176 65 51 27 0 353 184 100 190 
1000Gp1 1028 391 238 0 0 0 0 0 0 53 213 85 48 
1000Gp3 1345 134 212 0 457 0 0 0 0 23 408 103 8 
Public data 4235 943 645 103 633 65 51 27 0 429 805 288 246 
Qatar 1161 5 0 0 82 566 1 0 236 194 77 0 0 
Total 2373 525 450 0 457 0 0 0 0 76 621 188 56 
1 Summary of population structure analysis using ADMIXTURE. Genotypes were obtained for 2265 SNPs in a combined set of 5611 individuals, including 1161 Qataris 
(108 genomes and 1053 exomes), 215 s living in Qatar, 1862 from Human Origins dataset42, 1028 from 1000 Genomes Phase 1 not in Human Origins40, and 1345 from 
1000 Genomes Phase 3 not in Human Origins nor 1000 Genomes Phase 1. The set of SNPs used for the analysis were segregating in all three datasets, and were pruned 
using PLINK213 to exclude SNPs with Hardy-Weinberg equilibrium p-value < 1x10-6 and SNPs with linkage disequilibrium > 0.25 in 1000 SNP intervals (step size 25 
SNPs). ADMIXTURE analysis was conducted K=12 , based on lowest cross-validation error in a prior study16,17. The resulting ancestry proportions in 12 ancestral popula-
tions for each individual was used to assign each individual to a cluster for color-coding principal components analysis, based on the dominant ancestry for each individual. 
Shown is the total sample and number of individuals assigned to each of 12 clusters (K) for Qatari Exomes, Qatari Genomes, s in Qatar, Human Origins, 1000 Genomes 
Phase 1, 1000 Genomes Phase 3, and totals for public data (Human Origins, 1000 Genomes Phase 1 and 1000 Genomes Phase 3) and Qatari data (Qatar Genome and Qatar 
Exome).  Cluster names “inferred origin” is based on the major populations present in the cluster.
Supplemental Table IV. Relatives Identified in 1376 Qatari and Non-Qatari Exomes1 
 
Sample 
Inferred relation Kept Pairs (n) 1st 2nd 
Qatari Qatari 3 both 294 
Qatari Qatari 1 one 110 
Qatari Qatari 3 one 106 
Non-Qatari Non-Qatari 1 neither 87 
Qatari Qatari 2 one 55 
Qatari Qatari 1 neither 38 
Non-Qatari Non-Qatari 3 both 10 
Qatari Qatari 3 neither 9 
Qatari Qatari 2 neither 5 
Non-Qatari Non-Qatari 2 one 4 
Non-Qatari Non-Qatari 3 one 4 
Qatari Qatari 2 both 4 
Qatari Non-Qatari 1 neither 3 
Non-Qatari Non-Qatari 2 neither 2 
Qatari Non-Qatari 3 one 2 
Qatari Non-Qatari 1 one 1 
Qatari Non-Qatari 2 one 1 
Qatari Non-Qatari 3 both 1 
Non-Qatari Non-Qatari 1 both 0 
Non-Qatari Non-Qatari 2 both 0 
Non-Qatari Non-Qatari 3 neither 0 
Qatari Non-Qatari 1 both 0 
Qatari Non-Qatari 2 both 0 
Qatari Non-Qatari 2 neither 0 
Qatari Non-Qatari 3 neither 0 
Qatari Qatari 1 both 0 
1 SNPs were pruned from the initial 1376 individuals' exome datasets of 767,274 SNPs based on surrounding link-
age disequilibrium (LD) structure using PLINK 1.90's --indep-pairwise option with window sizes of 1000 SNPs, 
overlaps of 25 SNPs, and SNPs with LD > 0.25 pruned out. This left 381,028 SNPs for analysis. Manichaikul et 
al.'s19 program for estimating kinship coefficients between pairs of individuals, KING-robust v1.4, was then ap-
plied to this filtered dataset using the flag --kinship. None of the known pedigree information was included in the 
KING analysis. Degree of relatedness was inferred via cutoffs provided in the Manichaikul et al.19 paper, except 
for our second degree lower bound value (0.1101) which was chosen based on an analysis of SNP data from 1000 
Genomes and HapMap on individuals with known relationships. Columns 1 and 2 of the table denote whether in-
dividual 1 and two are currently living in Qatar or are Non-Qataris, respectively. Column 3 is the relationship in-
ferred by the KING-robust analysis. Column 4 denotes whether both, one, or neither individual was included in 
the subsequent analyses. Column 5 provides the number of pairs for which the prior columns' information applies 
to.
  
Supplemental Table V. Aggregated variants observed in 1005 unrelated Qatari (88 genomes, 917 exomes) and incorporated into the Qatar Reference Genome1 
 
 SNPs Indels 
Chr 
Integrated (n=1005) Genome (n=88) Exome 50 Mb (n=853) Exome 38 Mb (n=64) Genome (n=88) 
SNPs 
Novel Major alt allele 
SNPs 
Novel Major alt allele 
SNPs 
Novel 
Major alt al-
lele 
SNPs 
Novel 
Major alt al-
lele 
Indels 
Novel Major alt allele 
N % N % N % N % N % N % N % N % N % N % 
 All 20,937,965 2,975,232 14.21% 1,931,122 9.22% 20,838,516 2,956,681 14.19% 1,931,067 9.27% 167,723 18,175 10.84% 7,567 4.51% 84,133 5,973 7.10% 7,065 8.40% 5,452,613 3,182,624 58.37% 1,882,405 34.52% 
1 1,592,163 222,736 13.99% 149,248 9.37% 1,581,236 220,786 13.96% 149,224 9.44% 18,537 1,886 10.17% 860 4.64% 9,392 615 6.55% 781 8.32% 423,410 248,009 58.57% 143,511 33.89% 
2 1,709,761 240,085 14.04% 154,410 9.03% 1,703,529 238,883 14.02% 154,421 9.06% 10,370 1,155 11.14% 489 4.72% 5,296 383 7.23% 458 8.65% 439,507 255,079 58.04% 148,206 33.72% 
3 1,409,619 187,933 13.33% 129,413 9.18% 1,404,001 186,838 13.31% 129,414 9.22% 9,227 1,035 11.22% 400 4.34% 4,695 358 7.63% 385 8.20% 357,315 206,465 57.78% 120,288 33.66% 
4 1,445,319 195,681 13.54% 144,549 10.00% 1,441,704 195,004 13.53% 144,551 10.03% 6,261 621 9.92% 305 4.87% 3,286 246 7.49% 291 8.86% 370,841 217,409 58.63% 125,936 33.96% 
5 1,282,399 178,124 13.89% 114,208 8.91% 1,278,212 177,320 13.87% 114,208 8.93% 7,061 784 11.10% 388 5.49% 3,546 256 7.22% 366 10.32% 320,147 182,821 57.11% 109,029 34.06% 
6 1,254,721 169,944 13.54% 119,019 9.49% 1,249,428 168,993 13.53% 119,020 9.53% 9,406 1,143 12.15% 447 4.75% 5,019 535 10.66% 409 8.15% 332,004 195,950 59.02% 114,112 34.37% 
7 1,181,277 163,189 13.81% 105,329 8.92% 1,176,840 162,335 13.79% 105,324 8.95% 7,368 846 11.48% 262 3.56% 3,689 271 7.35% 261 7.08% 310,413 181,560 58.49% 103,381 33.30% 
8 1,121,946 154,901 13.81% 100,654 8.97% 1,118,463 154,271 13.79% 100,653 9.00% 5,741 620 10.80% 225 3.92% 2,778 185 6.66% 215 7.74% 263,130 153,087 58.18% 87,994 33.44% 
9 893,371 124,547 13.94% 81,215 9.09% 889,068 123,746 13.92% 81,222 9.14% 7,154 778 10.88% 290 4.05% 3,493 237 6.78% 270 7.73% 220,843 126,445 57.26% 74,180 33.59% 
10 1,011,674 132,809 13.13% 94,540 9.34% 1,007,822 132,100 13.11% 94,529 9.38% 6,692 663 9.91% 315 4.71% 3,453 229 6.63% 302 8.75% 262,781 152,899 58.18% 88,800 33.79% 
11 992,815 133,836 13.48% 101,238 10.20% 986,571 132,732 13.45% 101,237 10.26% 10,547 1,100 10.43% 568 5.39% 5,359 328 6.12% 537 10.02% 246,040 142,728 58.01% 82,771 33.64% 
12 950,274 127,170 13.38% 89,829 9.45% 945,483 126,273 13.36% 89,819 9.50% 8,066 871 10.80% 378 4.69% 4,078 280 6.87% 360 8.83% 258,803 149,851 57.90% 87,556 33.83% 
13 721,704 94,831 13.14% 75,313 10.44% 720,085 94,533 13.13% 75,309 10.46% 2,783 291 10.46% 148 5.32% 1,457 110 7.55% 141 9.68% 192,835 115,031 59.65% 66,223 34.34% 
14 657,214 90,851 13.82% 60,225 9.16% 654,196 90,281 13.80% 60,221 9.21% 5,139 585 11.38% 243 4.73% 2,603 163 6.26% 236 9.07% 169,405 97,754 57.70% 58,262 34.39% 
15 605,125 86,523 14.30% 55,833 9.23% 602,017 85,933 14.27% 55,831 9.27% 5,182 571 11.02% 233 4.50% 2,624 180 6.86% 225 8.57% 157,232 91,850 58.42% 54,406 34.60% 
16 667,442 97,950 14.68% 57,149 8.56% 662,638 97,058 14.65% 57,150 8.62% 7,894 882 11.17% 275 3.48% 3,630 270 7.44% 245 6.75% 161,821 94,228 58.23% 52,265 32.30% 
17 573,728 83,775 14.60% 49,208 8.58% 567,883 82,664 14.56% 49,198 8.66% 9,903 1,074 10.85% 422 4.26% 4,821 330 6.85% 388 8.05% 165,430 96,122 58.10% 55,824 33.74% 
18 567,901 74,034 13.04% 55,536 9.78% 566,489 73,776 13.02% 55,537 9.80% 2,472 248 10.03% 121 4.89% 1,290 85 6.59% 125 9.69% 146,951 85,698 58.32% 50,757 34.54% 
19 478,025 66,775 13.97% 39,669 8.30% 470,516 65,330 13.88% 39,674 8.43% 12,734 1,441 11.32% 499 3.92% 5,900 366 6.20% 449 7.61% 141,734 81,136 57.25% 47,778 33.71% 
20 456,002 58,746 12.88% 36,920 8.10% 453,008 58,231 12.85% 36,917 8.15% 5,099 475 9.32% 221 4.33% 2,482 151 6.08% 192 7.74% 120,911 72,303 59.80% 39,609 32.76% 
21 297,875 42,861 14.39% 30,364 10.19% 296,542 42,658 14.39% 30,363 10.24% 2,316 193 8.33% 124 5.35% 1,141 58 5.08% 111 9.73% 87,587 54,374 62.08% 26,897 30.71% 
22 289,339 39,574 13.68% 24,499 8.47% 286,767 39,142 13.65% 24,494 8.54% 4,404 432 9.81% 187 4.25% 2,082 118 5.67% 168 8.07% 76,727 46,370 60.44% 25,186 32.83% 
X 770,483 205,774 26.71% 61,856 8.03% 768,242 205,233 26.71% 61,854 8.05% 3,347 477 14.25% 166 4.96% 2,013 218 10.83% 149 7.40% 216,686 127,839 59.00% 115,824 53.45% 
Y 7,110 2,239 31.49% 886 12.46% 7,098 2,235 31.49% 885 12.47% 20 4 20.00% 1 5.00% 6 1 16.67% 1 16.67% 10,036 7,594 75.67% 3,593 35.80% 
MtDNA 678 344 50.74% 12 1.77% 678 326 48.08% 12 1.77% - - - - - - - - - - 24 22 91.67% 17 70.83% 
1. In order to build a reference genome tailored to the Qatari population, SNP and indel variants were identified in 1,005 unrelated Qataris and both novel and major alternate alleles (MAA) were quantified. A total of 1,161 Qatari DNA samples were sequenced, including 108 
selected for genome sequencing and 1,053 selected for exome sequencing. The exome sequencing subjects included n=67 sequenced on the Illumina platform using DNA captured with targets in the Agilent SureSelect Human All Exon 38 Mb platform (Exome38Mb), as well as 
n=1201 sequenced on the Illumina platform using DNA captured with targets in the Agilent SureSelect Human All Exon 51 Mb platform (Exome51Mb). Variants were identified in each genome or exome using the GATK best practices workflow8, and the data was integrated 
using batch-specific filters that ensured a consistent <0.73% novel SNP rate (compared to DbSNP build 146) across platforms in coding intervals covered by all three platforms. Related individuals were identified using variants in the intersection of the three platforms, 
exclusion of 1st degree and 2nd degree relatives resulted in n=1,005 Qatari, including n=88 genomes and n=917 exomes (n=64 Exome38Mb and n=853 Exome51Mb). The variants frequency was calculated across the n=1,005 Qataris individuals using a Python43 script, and 
novel variants were identified using VCFtools22. Shown is the total number of SNPs in the integrated set, the number and percentage of novel SNPs, and the number and percentage of MAA SNPs. The same columns are repeated for genome SNPs, Exome50Mb SNPs, 
Exome38Mb SNPs, and genome indels. The indels were identified using the CASAVA 1.9 workflow6.
 Supplemental Table VI. Impact of Using QTRG3 on Depth and Variant Sites in Quadruple Sequenced Qatari1 
 
 GRCh37 QTRG3 QTRG3 minus GRCh37 
Platform/batch Variants 
Mean 
depth Variants 
Mean 
depth 
Vari-
ants Mean depth 
Genome HiSeq 2500 369 31 331 32 -38 +1 
Genome HiSeq X 369 30 331 32 -38 +2 
Exome38Mb 369 83 331 79 -38 -4 
Exome51Mb 369 90 331 74 -38 -6 
1 In order to quantify differences in read depth and variant discovery between QTRG3 and GRCh37 references, sequence data from four 
platforms  (2 genome, 2 exome) was analyzed using GATK Best Practices Workflow8 twice, once using GRCh37 as the reference and 
once using QTRG3 as the reference. Shown are the results for Chr20 coding intervals covered in the intersection of the four platforms 
(Genome HiSeq 2500, Genome HiSeq X, Exome38Mb, Exome51Mb). Calls were filtered to sites covered at least 12* in all four plat-
forms. Shown is the total number of variants observed and mean depth at variant sites for GRCh37, total number of variants observed 
and mean depth at variant sites for QTRG3, and the difference in total variants and mean depth (negative means lower in QTRG3). 
Analysis was conducted using VCFtools22 and Python43 scripts.    
  
Supplemental Table VII. Coverage Depth Increase and Variant Call Reduction Using QTRG3 on a Large Qatari Family1 
 
Individual  
Depth at variant sites Variants 
Observed Increase Observed Reduction Expected 
GRCh37 QTRG3 X % GRCh37 QTRG3 N % N % E-O 
Mean 31 38 7 23% 4,843,626 4,086,955 756,671 16% 1,963,417 41% 25% 
QMD-27-01 30 34 4 14% 4,713,827 3,898,685 815,142 17% 1,962,206 42% 24% 
QMD-27-02 26 32 6 21% 4,777,169 4,017,524 759,645 16% 1,956,241 41% 25% 
QMD-27-04 30 37 7 24% 4,827,926 4,051,563 776,363 16% 1,970,911 41% 25% 
QMD-27-05 27 32 5 19% 4,841,023 4,096,170 744,853 15% 1,953,194 40% 25% 
QMD-27-06 30 38 8 26% 4,862,510 4,100,252 762,258 16% 1,968,086 40% 25% 
QMD-27-07 28 35 7 25% 4,788,903 4,063,026 725,877 15% 1,943,632 41% 25% 
QMD-27-08 32 40 8 24% 4,891,588 4,137,736 753,852 15% 1,961,483 40% 25% 
QMD-27-09 30 37 7 22% 4,862,523 4,106,822 755,701 16% 1,970,489 41% 25% 
QMD-27-10 31 38 7 23% 4,814,774 4,062,059 752,715 16% 1,961,938 41% 25% 
QMD-27-11 43 52 9 22% 4,949,852 4,199,328 750,524 15% 1,974,219 40% 25% 
QMD-27-12 30 36 6 19% 4,833,472 4,078,511 754,961 16% 1,969,131 41% 25% 
QMD-27-13 31 38 7 24% 4,870,552 4,114,454 756,098 16% 1,962,077 40% 25% 
QMD-27-14 32 41 9 27% 4,888,960 4,144,546 744,414 15% 1,969,268 40% 25% 
QMD-27-15 31 39 8 25% 4,889,792 4,137,013 752,779 15% 1,967,142 40% 25% 
QMD-27-16 31 39 8 24% 4,841,519 4,096,639 744,880 15% 1,961,233 41% 25% 
1. In order to study the impact of a modified reference on genome interpretation, n=15 Qatari genomes from a family of K=9 Persian an-
cestry were sequenced, and reads were mapped to both GRCh37 and QTRG3 and analyzed using GATK best practices8. Genome-wide 
mapped read depth at variant sites and number of variant sites per genome was quantified using VCFtools22, limited to sites covered 
with at least 12* depth. Shown is the mean and individual depth for GRCH37, depth for QTRG3, and the increased depth using 
QTRG3 (X depth and percentage of GRCh37 depth); the total number of variants in GRCh37 and QTRG3, and the reduction using 
QTRG3 (number and % of GRCh37); the expected reduction (number of flipped variants) and percentage, and the difference between 
observed and expected reduction (E-O).  
  
 Supplemental Table VIII. Evaluation of QTRG3 on a Diverse Panel of Qatari Exomes1 
 
Sample information 
Variants in Chr20 
Grch37 
QTRG3 
Expected Observed 
ID Batch 
ADMIXTURE 
Cluster 
Vari-
ants MAA Variants 
Reduction 
(%) 
Vari-
ants 
Reduction 
(%) 
DGMQ-31034 Exome51Mb K=8 Arab 1,937 758 1,179 39% 556 71% 
DGMQ-31094 Exome51Mb K=9 Persian 1,675 657 1,018 39% 470 72% 
DGMQ-31164 Exome51Mb K=5 Bedouin 1,667 674 993 40% 470 72% 
DGMQ-31203 Exome51Mb K=5 Bedouin 1,962 766 1,196 39% 548 72% 
DGMQ-31517 Exome51Mb K=4 South Asian 1,737 641 1,096 37% 557 68% 
DGMQ-31721 Exome51Mb K=5 Bedouin 2,250 878 1,372 39% 589 74% 
DGMQ-31728 Exome51Mb K=9 Persian 1,587 564 1,023 36% 503 68% 
DGMQ-31790 Exome51Mb K=9 Persian 2,204 842 1,362 38% 587 73% 
DGMQ-32543 Exome51Mb K=8 Arab 1,734 733 1,001 42% 444 74% 
DGMQ-32513 Exome51Mb K=10 Sub-Saharan African 2,397 733 1,664 31% 788 67% 
DGMQ-33173 Exome51Mb K=10 Sub-Saharan African 2,164 682 1,482 32% 640 70% 
DGMQ-33708 Exome51Mb K=10 Sub-Saharan African 2,092 636 1,456 30% 681 67% 
DGMQ-33147 Exome51Mb K=8 Arab 1,598 622 976 39% 476 70% 
DGMQ-33553 Exome51Mb K=5 Bedouin 1,866 750 1,116 40% 450 76% 
DGMQ-33557 Exome51Mb K=5 Bedouin 1,847 749 1,098 41% 515 72% 
DGMQ-31923 Exome51Mb K=8 Arab 1,851 723 1,128 39% 549 70% 
1 In order to quantify the impact of using the QTRG3 reference on variant discovery, n=16 exomes from diverse ancestries were mapped 
to both the GRCh37 and QTRG3 reference genomes, and variants were identified using GATK best practices8. Shown is the sample ID, 
the sequencing batch, the inferred ancestry cluster, the number of variants observed with respect to GRCh37 on Chr20 at, the number of 
variants that were modified in the reference that are present in this individual, the expected and observed number of variants and per-
cent reduction of variants compared to GRCh37 mapping. The expected variants is equal to the GRCh37 variants minus the flipped in 
QTRG3 variants, while the observed variants is based on mapping to QTRG3. The reduction is significant with a Chi-square test p 
value < 0.001. 
 Supplemental Table IX. Functional Classification of Variants in Qatar1 
 
Impact Function 
All variants Major alt alleles (MAA) 
n % n % 
 All 26,390,578 100.00% 3,827,678 100.00% 
High Likely pathogenic 12,721 0.05% 1,622 0.04% 
Moderate Potentially pathogenic 164,821 0.62% 8,944 0.23% 
Low Unlikely pathogenic 4,357,128 16.51% 621,631 16.24% 
Modifier Likely benign 21,855,908 82.82% 3,195,481 83.48% 
High Frameshift variant 2,888 0.01% 617.0 0.02% 
 Stop gained 2,361 0.01% 43.0 0.00% 
 Splice donor variant & intron variant 2,193 0.01% 268.0 0.01% 
 Splice acceptor variant & intron variant 1,799 0.01% 289.0 0.01% 
 Protein protein contact 1,023 <0.01% 18.0 <0.01% 
 Frameshift variant & stop gained 421 <0.01% 26.0 <0.01% 
 Start lost 374 <0.01% 21.0 <0.01% 
 Stop lost 293 <0.01% 38.0 <0.01% 
 Frameshift variant & splice region variant 213 <0.01% 72.0 <0.01% 
 Stop gained & inframe insertion 101 <0.01% 8.0 <0.01% 
 Splice donor variant & splice region variant & intron variant & non coding exon variant 94 <0.01% 14.0 <0.01% 
 Splice acceptor variant & splice region variant & intron variant 94 <0.01% 37.0 <0.01% 
 Splice acceptor variant & splice region variant & intron variant & non coding exon variant 87 <0.01% 18.0 <0.01% 
 Stop gained & splice region variant 80 <0.01% 3.0 <0.01% 
 Stop gained & disruptive inframe insertion 70 <0.01% 5.0 <0.01% 
 Frameshift variant & stop gained & splice region variant 68 <0.01% 12.0 <0.01% 
 Splice donor variant & splice region variant & intron variant 61 <0.01% 17.0 <0.01% 
 Splice acceptor variant & splice donor variant & intron variant 55 <0.01% 35.0 <0.01% 
 Splice acceptor variant & splice donor variant & splice region variant & intron variant & non coding exon variant 49 <0.01% 7.0 <0.01% 
 Frameshift variant & stop lost 38 <0.01% 10.0 <0.01% 
 Frameshift variant & start lost 37 <0.01% 12.0 <0.01% 
 Frameshift variant & splice acceptor variant & splice region variant & intron variant 28 <0.01% 7.0 <0.01% 
 Splice donor variant & splice region variant & 5 prime UTR variant & intron variant 25 <0.01% 2.0 <0.01% 
 Frameshift variant & splice donor variant & splice region variant & intron variant 24 <0.01% 6.0 <0.01% 
 Exon loss variant & splice acceptor variant & splice donor variant & splice region variant & intron variant 23 <0.01% 0.0 <0.01% 
 Stop lost & splice region variant 19 <0.01% 4.0 <0.01% 
 Transcript ablation 18 <0.01% 3.0 <0.01% 
 Stop gained & inframe insertion & splice region variant 15 <0.01% 0.0 <0.01% 
 Splice acceptor variant & splice donor variant & splice region variant & intron variant 14 <0.01% 3.0 <0.01% 
 Frameshift variant & stop lost & splice region variant 10 <0.01% 0.0 <0.01% 
 Start lost & splice region variant 10 <0.01% 1.0 <0.01% 
 Splice donor variant & disruptive inframe deletion & splice region variant & intron variant 9 <0.01% 2.0 <0.01% 
Supplemental Table IX. Functional Classification of Variants in Qatar1 (cont., page 2) 
Impact Function 
All variants Major alt alleles (MAA) 
n % n % 
 Splice donor variant & splice region variant & 3 prime UTR variant & intron variant 8 <0.01% 3.0 <0.01% 
 Start lost & inframe deletion 8 <0.01% 3.0 <0.01% 
 Splice acceptor variant & splice region variant & 3 prime UTR variant & intron variant 8 <0.01% 5.0 <0.01% 
 Stop lost & inframe deletion 7 <0.01% 0.0 <0.01% 
 Splice acceptor variant & inframe deletion & splice region variant & intron variant 6 <0.01% 2.0 <0.01% 
 Splice donor variant & 5 prime UTR variant & intron variant 6 <0.01% 2.0 <0.01% 
 Splice acceptor variant & 5 prime UTR variant & intron variant 5 <0.01% 0.0 <0.01% 
 Frameshift variant & splice acceptor variant & splice donor variant & splice region variant & intron variant 5 <0.01% 0.0 <0.01% 
 Frameshift variant & start lost & splice region variant 5 <0.01% 2.0 <0.01% 
 Splice acceptor variant & splice region variant & 5 prime UTR variant & intron variant 5 <0.01% 0.0 <0.01% 
 Stop gained & disruptive inframe insertion & splice region variant 5 <0.01% 0.0 <0.01% 
 Start lost & disruptive inframe insertion 4 <0.01% 1.0 <0.01% 
 Splice acceptor variant & splice donor variant & 5 prime UTR truncation & exon loss variant & splice region variant & intron variant 4 <0.01% 0.0 <0.01% 
 Splice donor variant & 5 prime UTR truncation & exon loss variant & splice region variant & intron variant 4 <0.01% 0.0 <0.01% 
 Frameshift variant & missense variant 3 <0.01% 0.0 <0.01% 
 Splice acceptor variant & splice donor variant & splice region variant & 3 prime UTR variant & intron variant 3 <0.01% 0.0 <0.01% 
 Splice donor variant & 3 prime UTR variant & intron variant 3 <0.01% 0.0 <0.01% 
 Exon loss variant & splice acceptor variant & splice donor variant & 3 prime UTR truncation & exon loss variant & splice region variant & intron variant 3 <0.01% 1.0 <0.01% 
 Splice acceptor variant & disruptive inframe deletion & splice region variant & intron variant 3 <0.01% 1.0 <0.01% 
 Splice acceptor variant & splice donor variant & disruptive inframe deletion & splice region variant & intron variant 3 <0.01% 0.0 <0.01% 
 Splice donor variant & inframe deletion & splice region variant & intron variant 3 <0.01% 0.0 <0.01% 
 Start lost & inframe insertion 3 <0.01% 1.0 <0.01% 
 Stop gained & disruptive inframe deletion 3 <0.01% 0.0 <0.01% 
 Frameshift variant & missense variant & splice region variant 2 <0.01% 0.0 <0.01% 
 Exon loss variant & splice acceptor variant & splice region variant & intron variant 2 <0.01% 0.0 <0.01% 
 Exon loss variant & splice donor variant & splice region variant & intron variant 2 <0.01% 2.0 <0.01% 
 Exon loss variant & splice region variant 2 <0.01% 0.0 <0.01% 
 Start lost & disruptive inframe deletion 2 <0.01% 0.0 <0.01% 
 Stop lost & inframe deletion & splice region variant 2 <0.01% 0.0 <0.01% 
 Exon loss variant 1 <0.01% 0.0 <0.01% 
 Frameshift variant & splice acceptor variant & missense variant & splice region variant & intron variant 1 <0.01% 0.0 <0.01% 
 Frameshift variant & splice donor variant & splice region variant & synonymous variant & intron variant 1 <0.01% 0.0 <0.01% 
 Frameshift variant & stop gained & stop retained variant 1 <0.01% 0.0 <0.01% 
 Splice acceptor variant & missense variant & inframe insertion & splice region variant & intron variant 1 <0.01% 0.0 <0.01% 
 Splice acceptor variant & splice donor variant & inframe deletion & splice region variant & intron variant 1 <0.01% 0.0 <0.01% 
 Splice acceptor variant & splice donor variant & splice region variant & 5 prime UTR variant & intron variant 1 <0.01% 0.0 <0.01% 
 Stop gained & splice acceptor variant & missense variant & inframe insertion & splice region variant & intron variant 1 <0.01% 1.0 <0.01% 
Moderate Missense variant 144,405 0.55% 6,039.0 0.16% 
 Sequence feature 13,953 0.05% 1,950.0 0.05% 
 Missense variant & splice region variant 3,179 0.01% 138.0 0.00% 
Supplemental Table IX. Functional Classification of Variants in Qatar1 (cont., page 3) 
Impact Function 
All variants Major alt alleles (MAA) 
n % n % 
 Disruptive inframe deletion 1,208 <0.01% 292.0 0.01% 
 Disruptive inframe insertion 764 <0.01% 214.0 0.01% 
 Inframe insertion 662 <0.01% 173.0 <0.01% 
 Inframe deletion 562 <0.01% 124.0 <0.01% 
 Inframe insertion & splice region variant 48 <0.01% 9.0 <0.01% 
 Disruptive inframe deletion & splice region variant 13 <0.01% 1.0 <0.01% 
 Inframe deletion & splice region variant 12 <0.01% 3.0 <0.01% 
 Disruptive inframe insertion & splice region variant 11 <0.01% 0.0 <0.01% 
 Missense variant & disruptive inframe insertion 1 <0.01% 0.0 <0.01% 
 5 prime UTR truncation & exon loss variant 1 <0.01% 0.0 <0.01% 
 Missense variant & inframe insertion 1 <0.01% 1.0 <0.01% 
 Missense variant & inframe insertion & splice region variant 1 <0.01% 0.0 <0.01% 
Low Sequence feature 4,191,317 15.88% 607,205.0 15.86% 
 Synonymous variant 108,870 0.41% 6,041.0 0.16% 
 Splice region variant & intron variant 24,115 0.09% 4,477.0 0.12% 
 5 prime UTR premature start codon gain variant 10,353 0.04% 726.0 0.02% 
 TF binding site variant 10,053 0.04% 1,388.0 0.04% 
 Splice region variant & non coding exon variant 6,253 0.02% 1,103.0 0.03% 
 Splice region variant 2,830 0.01% 469.0 0.01% 
 Splice region variant & synonymous variant 2,551 0.01% 130.0 <0.01% 
 TFBS ablation 636 <0.01% 83.0 <0.01% 
 Stop retained variant 109 <0.01% 6.0 <0.01% 
 Initiator codon variant 27 <0.01% 2.0 <0.01% 
 Splice region variant & stop retained variant 13 <0.01% 0.0 <0.01% 
 Splice region variant & downstream gene variant 1 <0.01% 1.0 <0.01% 
Modifier Intergenic region 10,100,190 38.27% 1,493,966.0 39.03% 
 Intron variant 6,339,378 24.02% 914,967.0 23.90% 
 Upstream gene variant 2,912,384 11.04% 425,612.0 11.12% 
 Downstream gene variant 2,132,880 8.08% 311,645.0 8.14% 
 3 prime UTR variant 230,874 0.87% 32,038.0 0.84% 
 Non coding exon variant 74,461 0.28% 9,087.0 0.24% 
 5 prime UTR variant 58,106 0.22% 7,413.0 0.19% 
 TF binding site variant 5,501 0.02% 424.0 0.01% 
 Intragenic variant 2,134 0.01% 329.0 0.01% 
1 Variants (SNPs and indels) were functionally annotated using SnpEff29 using ENSEMBL build 7528 gene models. Shown are the counts of variants, grouped by functional category. 
The number of variants is shown for all SNPs and for major allele SNPs, and the percentages of the total number of SNPs (top row). Top section lists all SNPs, middle section list 
subsets of potentially pathogenic and unlikely pathogenic, and third section lists details of each annotated variant category. Categories are organized from top to bottom by decreasing 
pathogenicity and decreasing n. 
  
Supplemental Table X. Known Pathogenic Mendelian Mutations Observed in Two or More Qataris1 
 
Disease(s) 
Inheritance 
model 
Reference 
PMID Gene 
Gene 
MIM Chr 
Position 
rsID 
cDNA 
Change A.A. Change 
# Q - 
Hom 
# Q - 
Het 
Qat-
MAF 
ExAC-
MAF GRCh37 QTRG3 
Cowden-like Syndrome Dominant (LO) 18678321 SDHB 185470 1 17354297 17354627 rs33927012 c.487T>C p.Ser163Pro 0 12 0.60% 1.300% 
Dominant deafness Type 2B Dominant 9843210 GJB3 603324 1 35250910 35223785 rs74315318 c.547G>A p.Glu183Lys 0 2 0.12% 0.051% 
Mcad Deficiency Dominant (SD) 9158144 ACADM 607008 1 76199288 76198878 rs121434283 c.461C>T p.Thr154Ile 0 7 0.41% 0.001% 
Diamond-blackfan anemia Dominant (RP) 19061985 RPL5 603634 1 93301840 35817017 rs121434406 c.418G>A p.Gly140Ser 0 3 1.71% 0.013% 
Fundus Flavimaculatus Dominant (SD) 9781034 ABCA4 601691 1 94473287 94472343 rs28938473 c.5908C>T p.Leu1970Phe 0 2 0.12% 0.290% 
Stargardt Disease 1 Dominant (SD) 9973280 ABCA4 601691 1 94473807 94472863 rs1800553 c.5882G>A p.Gly1961Glu 0 36 1.79% 0.505% 
Stargardt Disease 1 Dominant (SD) 9054934 ABCA4 601691 1 94512602 94511636 rs58331765 c.2791G>A p.Val931Met 0 2 0.11% 0.049% 
Erythrocyte Lactate Transporter Deficiency Dominant (M) 10590411 SLC16A1 600682 1 113456602 113455493 rs72552271 c.1414G>A p.Gly472Arg 0 4 0.23% 0.015% 
Thrombophilia due to Factor 5 Leiden Dominant (RP) 3110773 F5 612309 1 169519049 169517298 rs6025 c.1601A>G p.Gln534Arg 0 14 0.70% 97.800% 
Hereditary Prostate Cancer Dominant (LO) 11799394 RNASEL 180435 1 182555149 182553554 rs74315364 c.793G>T p.Glu265* 0 5 0.29% 0.399% 
Familial autoinflammatory Syndrome Dominant 49161 NLRP3 606416 1 247587343 247585369 rs121908147 c.598G>A p.Val200Met 0 10 0.55% 0.823% 
Primary Glaucoma Dominant (LO) 15342693 CYP1B1 601771 2 38302291 38302637 rs9282671 c.241T>A p.Tyr81Asn 0 3 0.19% 0.345% 
Atrioventricularseptal Defect Dominant (RP) 12632326 CRELD1 607170 3 9985136 9984961 rs28942091 c.985C>T p.Arg329Cys 0 2 0.12% 0.063% 
Heterotaxy Syndrome Dominant 9916847 ACVR2B 602730 3 38518844 38518610 rs121434437 c.119G>A p.Arg40His 0 5 0.27% 0.137% 
Telomere-related Bone Marrow Failure Dominant (RP) 15814878 TERT 187270 5 1294397 1294427 rs121918661 c.604G>A p.Ala202Thr 0 2 0.12% 0.023% 
Familial adenomatous polyposis 1 Dominant (LO) 11001924 APC 611731 5 112175240 112175677 rs1801166 c.3949G>C p.Glu1317Gln 0 32 1.59% 0.413% 
Tetralogy of Fallot Dominant (RP) 16418214 NKX2-5 600584 5 172662014 172662883 rs28936670 c.73C>T p.Arg25Cys 0 11 0.56% 0.371% 
Tetralogy of Fallot Dominant (RP) 11714651 NKX2-5 600584 5 172662026 172662895 rs104893904 c.61G>C p.Glu21Gln 0 4 0.24% 0.078% 
Thiopurine S-methyltransferase Deficiency Dominant (SD) 9931346 TPMT 187680 6 18130993 18131172 rs56161402 c.644G>A p.Arg215His 0 4 0.26% 0.204% 
Hemochromatosis Dominant 10194428 HFE 613609 6 26091185 26091026 rs1800730 c.193A>T p.Ser65Cys 0 2 0.12% 1.000% 
Galbladder Disease 1 Dominant (LO) 3459187 ABCB4 171060 7 87082273 20682533 rs58238559 c.523A>G p.Thr175Ala 1 9 0.64% 1.100% 
Prostate Cancer Dominant 12244320 MSR1 153622 8 16012594 16012318 rs41341748 c.931C>T p.Arg311* 0 6 0.35% 0.735% 
Prostate Cancer Dominant 12244320 MSR1 153622 8 16026077 16025799 rs72552387 c.574G>T p.Asp192Tyr 0 10 0.50% 0.197% 
Familial Hyperlipidemia Dominant (RP) 8541837 LPL 609708 8 19813529 19812860 rs268 c.953A>G p.Asn318Ser 0 4 0.23% 1.300% 
Multiple Endocrine Neoplasia Dominant (RP) 12466368 RET 164761 10 43609990 43609141 rs77711105 c.1942G>A p.Val648Ile 0 5 0.27% 0.009% 
Recessive Visceral Heterotaxy 5 Dominant (RP) 9354794 NODAL 601265 10 72195385 72194808 rs104894169 c.548G>A p.Arg183Gln 0 2 0.12% 0.012% 
Dilated Cardiomyopathy Dominant (LO) 14662268 LDB3 605906 10 88446830 88445588 rs121908338 c.694G>A p.Asp232Asn 0 4 2.27% 0.454% 
Cowden-like Syndrome Dominant (LO) 18678321 SDHD 602690 11 111958677 111957252 rs11214077 c.149A>G p.His50Arg 0 3 0.16% 0.652% 
Acute Porphyria Dominant (M) 8262523 HMBS 609806 11 118963216 118961755 rs118204113 c.754G>A p.Ala252Thr 0 8 0.43% - 
Cirrhosis Dominant (LO) 11372009 KRT8 148060 12 53298582 53298312 rs11554495 c.268G>T p.Gly90Cys 0 3 0.36% 0.505% 
Cirrhosis Dominant (LO) 11372009 KRT8 148060 12 53298606 53298336 rs57749775 c.244T>C p.Tyr82His 0 2 0.20% 0.199% 
Dominant deafness Type 3B Dominant 10471490 GJB6 604418 13 20797606 20717395 rs104894414 c.14C>T p.Thr5Met 0 2 0.12% 0.003% 
Hereditary Nonpolyposis Colon Cancer Type 
7 Dominant (RP) 12702580 MLH3 604395 14 75514138 75514289 rs28756990 c.2221G>T p.Val741Phe 0 31 1.54% 1.500% 
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Childhood absence epilepsy 5 Dominant (RP) 18514161 GABRB3 137192 15 27018841 27019151 rs25409 c.31C>T p.Pro11Ser 0 9 0.56% 0.235% 
Spherocytosis Type 4 Anemia, Band 3 Tuca-
loosa Dominant 1378323 SLC4A1 109270 17 42335888 42335820 rs28931583 c.980C>G p.Pro327Arg 0 4 0.21% 0.024% 
Hypophosphatemic osteoporosis Dominant (LO) 18784102 SLC9A3R1 604990 17 72745313 72744916 rs35910969 c.328C>G p.Leu110Val 0 8 0.58% 0.869% 
Hypogonadotropic hypogonadism Dominant 18272894 KISS1R 604161 19 920708 920748 rs121908499 c.1157G>C p.Arg386Pro 0 2 0.11% 0.011% 
Noninsullin-dependent Diabetes Mellitus Dominant (RP) 8432414 INSR 147670 19 7125518 7125639 rs1799816 c.3034G>A p.Val1012Met 0 37 1.84% 0.898% 
Cystinuria Dominant 11157794 SLC7A9 604144 19 33334838 33334502 rs121908484 c.997C>T p.Arg333Trp 0 2 0.13% 0.009% 
Cystinuria Dominant 11157794 SLC7A9 604144 19 33353427 33353087 rs79389353 c.544G>A p.Ala182Thr 0 3 0.19% 0.274% 
Primary Open Angle Glaucoma Dominant (RP) 19765683 NTF4 162662 19 49564992 49528991 rs61732310 c.263C>T p.Ala88Val 0 17 0.90% 0.469% 
Dominant Deafness Dominant (M) 15015131 MYH14 608568 19 50747534 50747363 rs119103280 c.1150G>T p.Gly384Cys 0 3 1.71% 0.285% 
Familial Hypertrophic Cardiomyopathy Dominant (LO) 15070570 TNNI3 191044 19 55667607 55667367 rs77615401 c.244C>T p.Pro82Ser 0 5 0.25% 0.164% 
Keratoconus Dominant (LO) 15623752 VSX1 605020 20 25062683 25062503 rs74315436 c.50T>C p.Leu17Pro 0 2 0.17% 0.008% 
Hypertrophic Cardiomyopathy Dominant (M) 11733062 MYLK2 606566 20 30408160 30408106 rs121908108 c.284C>A p.Ala95Glu 0 8 0.43% 0.078% 
Long QT Syndrome Dominant (M) 10219239 KCNE2 603796 21 35742947 35743144 rs74315448 c.170T>C p.Ile57Thr 1 32 1.81% 0.088% 
Becker Muscular Dystrophy Dominant (M) 7881286 DMD 300377 X 31496398 31495994 rs1800279 c.8762A>G p.His2921Arg 1 38 3.43% 2.700% 
Duchenne Muscular Dystrophy Dominant 7881286 DMD 300377 X 31496431 31496027 rs41305353 c.8729A>T p.Glu2910Val 0 15 1.29% 2.100% 
Non-fatal, non-progressive encephalopathy Dominant (M) 11238684 MECP2 300005 X 153295997 153295135 rs61753971 c.1318G>A p.Gly440Ser 0 3 0.28% 0.012% 
Recessive early-onset Parkinson Disease Recessive 12953260 PARK7 602533 1 8044990 8045123 rs74315352 c.446A>C p.Asp149Ala 0 3 0.16% 0.020% 
Masp2 Deficiency Recessive 12904520 MASP2 605102 1 11106666 11106808 rs72550870 c.359A>G p.Asp120Gly 0 3 0.16% 2.200% 
Limb-girdle muscular dystrophy Recessive 18195152 POMGNT1 606822 1 46655645 46656025 rs74374973 c.1666G>A p.Asp556Asn 0 6 0.33% 0.893% 
Cystathioniuria Recessive 12574942 CTH 607657 1 70881670 70777863 rs28941785 c.200C>T p.Thr67Ile 0 3 0.16% 0.647% 
Myopathy due to Myoadenylate Deaminase 
Deficiency Recessive 10996775 AMPD1 102770 1 115220593 110169903 rs35859650 c.1261C>T p.Arg421Trp 0 4 0.21% 0.068% 
Gaucher Disease type I Recessive 22713811 GBA 606463 1 155205043 155183055 rs421016 c.1448T>C p.Leu483Pro 0 3 0.18% 0.316% 
Recessive spherocytosis Type 3 Recessive 3785322 SPTA1 182860 1 158624528 158623150 rs35948326 c.2909C>A p.Ala970Asp 0 11 0.64% 3.300% 
Porphyria Recessive 11286631 PPOX 600923 1 161138933 161137548 rs12735723 c.767C>G p.Pro256Arg 0 2 0.12% 0.665% 
Nephrotic Syndrome Recessive 12464671 NPHS2 604766 1 179526214 179524646 rs61747728 c.686G>A p.Arg229Gln 0 18 0.98% 2.900% 
Nephrotic Syndrome Recessive 10742096 NPHS2 604766 1 179544941 179543383 rs74315344 c.59C>T p.Pro20Leu 0 6 0.40% 0.195% 
Primary Glaucoma Recessive (RP) 10655546 CYP1B1 601771 2 38298394 38298741 rs79204362 c.1103G>A p.Arg368His 0 48 2.39% 0.596% 
Rod Monochromacy (colorblindness) Recessive 9662398 CNGA3 600053 2 99012480 99012626 rs104893613 c.859C>T p.Arg287Trp 0 3 0.18% 0.014% 
Recessive Thrombophilia due to Protein C 
Deficiency Recessive 1678832 PROC 612283 2 128186038 128185850 rs121918144 c.1067C>T p.Ala356Val 0 7 0.41% - 
Odontoonychodermal Dysplasia (Tooth agen-
esis) Recessive 19559398 WNT10A 606268 2 219755011 219752068 rs121908120 c.682T>A p.Phe228Ile 0 9 0.50% 1.300% 
Long QT Syndrome Recessive 17060380 CAV3 601253 3 8787330 8787143 rs72546668 c.233C>T p.Thr78Met 0 20 1.01% 0.303% 
Biotinidase Defieicency Recessive 10400129 BTD 609019 3 15686693 15686407 rs13078881 c.1336G>C p.Asp446His 0 35 1.74% 3.200% 
Hurler Syndrome Recessive 8328452 IDUA 252800 4 996555 996554 rs11934801 c.1291G>C p.Gly431Arg 0 3 1.71% 0.388% 
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Hypogonadotropic hypogonadism Recessive 9371856 GNRHR 138850 4 68619737 68618073 rs104893836 c.317A>G p.Gln106Arg 0 2 0.12% 0.252% 
Recessive Dyskeratosis Congenita Recessive 15814878 TERT 187270 5 1293767 1293797 rs34094720 c.1234C>T p.His412Tyr 1 3 0.29% 0.224% 
Recessive Neuropathy Recessive 16399879 CCT5 610150 5 10256175 10256372 rs118203986 c.440A>G p.His147Arg 1 8 0.53% 0.004% 
Central hypoventilation Syndrome Recessive 9497256 GDNF 600837 5 37816112 37816039 rs36119840 c.328C>T p.Arg110Trp 0 2 0.11% 0.221% 
C7 Deficiency Recessive 9218625 C7 217070 5 40955530 40955516 rs121964921 c.1135G>C p.Gly379Arg 0 2 1.14% 0.013% 
Laron Dwarfism Recessive (M) 9814495 GHR 600946 5 42699970 42699907 rs6413484 c.484G>A p.Val162Ile 0 3 0.18% 0.137% 
Laron Dwarfism Recessive (M) 7565946 GHR 600946 5 42700021 42699958 rs121909362 c.535C>T p.Arg179Cys 0 2 0.12% 0.409% 
Progressive Arthropathy Recessive 10471507 WISP3 603400 6 112382323 112381757 rs17073260 c.232C>T p.Arg78Cys 1 11 0.65% 0.937% 
Recessive Parkinson disease 2 (juvenile) Recessive 11487568 PARK2 602544 6 162683724 162683679 rs55774500 c.245C>A p.Ala82Glu 0 4 0.21% 0.474% 
Maple syrup Urine Disease Recessive 9934985 DLD 238331 7 107555951 107555906 rs121964990 c.685G>T p.Gly229Cys 0 4 0.23% 0.026% 
Congenital Bilateral Absense of the Vas Def-
erens Recessive 1545465 CFTR 602421 7 117230454 117230209 rs1800098 c.1727G>C p.Gly576Ala 0 4 0.24% 0.513% 
Cystic Fibrosis Recessive 7504969 CFTR 602421 7 117267807 117267564 rs75389940 c.3700A>G p.Ile1234Val 0 9 0.53% 0.001% 
Recessive myotonia Recessive 11113225 CLCN1 118425 7 143048886 143048936 rs80356706 c.2795C>T p.Pro932Leu 0 2 0.12% 0.014% 
Retinitis pigmentosa Recessive 15863674 RP1 603937 8 55537560 55536834 rs77775126 c.1118C>T p.Thr373Ile 2 34 1.89% 1.300% 
Recessive myopathy Recessive 11528398 GNE 603824 9 36217396 36217255 rs28937594 c.2228T>C p.Met743Thr 0 2 0.12% 0.003% 
Aldolase B Deficiency Recessive 3383242 ALDOB 612724 9 104189856 104188749 rs1800546 c.448G>C p.Ala150Pro 0 3 0.18% 0.270% 
Cockayne Syndrome Type B Recessive 9443879 ERCC6 609413 10 50678722 50678022 rs4253208 c.3284C>G p.Pro1095Arg 0 4 0.23% 0.378% 
Hemophagocytic Lymphohistiocytosis (in-
cluding non-hodgkin lymphoma) Recessive (RP) 12229880 PRF1 170280 10 72360387 72359805 rs35947132 c.272C>T p.Ala91Val 0 9 0.50% 3.100% 
Dubin-Johnson Syndrome Recessive 11477083 ABCC2 601107 10 101595950 101594812 rs72558201 c.3517A>T p.Ile1173Phe 0 2 0.12% 0.002% 
Beta-Thalassemia 
Recessive (M; 
Mod) 16114182 HBB 141900 11 5248173 5248158 rs33950507 c.79G>A p.Glu27Lys 0 4 0.21% 0.029% 
Sickle Cell Anemia Recessive 13852872 HBB 141900 11 5248232 5248217 rs334 c.20A>T p.Glu7Val 0 3 1.71% 0.439% 
Beta-Thalassemia 
Recessive (M; 
Mod) 2467892 HBD 142000 11 5255582 5248155 rs35152987 c.82G>T p.Ala28Ser 0 7 0.41% 0.223% 
Congenital Central Hypoventilation Syn-
drome Recessive 11840487 BDNF 113505 11 27680107 27678988 rs8192466 c.251C>T p.Thr84Ile 0 24 1.19% 0.109% 
Omenn Syndrome Recessive 9630231 RAG1 179615 11 36596041 36594713 rs104894291 c.1187G>A p.Arg396His 0 2 0.12% 0.002% 
Oculocutaneous Albinism Type IA Recessive 1642278 TYR 606933 11 88911770 88910230 rs63159160 c.649C>T p.Arg217Trp 0 5 0.25% 0.020% 
Oculocutaneous Albinism Type IB Recessive 5516239 TYR 606933 11 89017973 49435662 rs104894313 c.1217C>T p.Pro406Leu 1 3 0.27% 0.249% 
Hyperalphalipoproteinemia 2 Recessive 24941082 APOC3 107720 11 116701353 116699867 rs76353203 c.109C>T p.Arg37* 0 2 1.14% 0.068% 
Recessive Bartter Syndrome Recessive 8841184 KCNJ1 600359 11 128709126 17408421 rs59172778 c.1070T>C p.Met357Thr 0 6 0.32% 0.802% 
Adrenoleukodystrophy Recessive 7719337 PEX5 600414 12 7362296 7362469 rs61752138 c.1641T>G p.Asn547Lys 0 2 0.12% - 
Recessive Nephrogenic Diabetes Insipidus Recessive 9048343 AQP2 107777 12 50344816 50344595 rs104894331 c.203A>C p.Asn68Thr 0 24 1.33% 4.700% 
Vitamin D Hydroxylation-Defiiency Rickets Recessive 12050193 CYP27B1 609506 12 58159103 58158702 rs118204012 c.566A>G p.Glu189Gly 0 8 0.45% 0.121% 
Hyper-IgD Syndrome Recessive 10369261 MVK 251170 12 110034320 110034227 rs28934897 c.1129G>A p.Val377Ile 0 6 0.32% 0.140% 
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Peeling skin Syndrome  Recessive 16380904 TGM5 603805 15 43552349 43552928 rs112292549 c.337G>T p.Gly113Cys 0 3 0.18% 0.259% 
Tay-sachs Disease Recessive 2140574 HEXA 606869 15 72637817 72638091 rs121907956 c.1529G>A p.Arg510His 0 2 0.12% 0.007% 
Fumarylacetoacetase Deficiency Recessive 7977370 FAH 613871 15 80472526 80472708 rs11555096 c.1021C>T p.Arg341Trp 1 9 0.55% 1.700% 
Familial Mediterranean Fever Recessive 9668175 MEFV 608107 16 3293403 3293353 rs104895094 c.2084A>G p.Lys695Arg 0 3 0.18% 0.550% 
Bardet-Biedl Syndrome 2 
Recessive (Di-
genic) 11567139 BBS2 606151 16 56548501 56548300 rs4784677 c.209G>A p.Asn70Ser 1 10 0.60% 0.600% 
Congenital Myasthenic syndrome Recessive 8755487 CHRNE 100725 17 4805239 4805392 rs121909516 c.488C>G p.Ser163Trp 0 4 0.24% 0.003% 
Congenital ichthyosiform Erythrodermia Recessive 16116617 ALOXE3 607206 17 8015486 7946150 rs121434235 c.1177T>A p.Leu393Met 0 12 0.70% 0.558% 
Smith-Magenic Syndrome Recessive 11735029 MYO15A 602666 17 18051447 18051368 rs121908970 c.6614C>T p.Thr2205Ile 0 2 0.12% 0.417% 
Myeloperoxidase Deficiency Recessive 9354683 MPO 606989 17 56356502 56272604 rs56378716 c.848T>C p.Met283Thr 0 12 0.64% 1.000% 
Erythropoietic protoporphyria Recessive 1755842 FECH 612386 18 55226380 55226136 rs118204037 c.819G>A p.Met273Ile 0 17 0.85% 0.109% 
Hypogonadotropic hypogonadism Recessive 17164310 KISS1R 604161 19 918604 918644 rs104894703 c.305T>C p.Leu102Pro 0 5 0.30% 0.003% 
Dominant hyperlipoprotenemia Type 3 Recessive 9649566 APOE 107741 19 45412040 45411899 rs769455 c.487C>T p.Arg163Cys 0 4 0.35% 0.123% 
Limb-girdle muscular dystrophy Recessive 14647208 FKRP 606596 19 47258942 47258803 rs104894683 c.235G>A p.Val79Met 0 6 0.35% 0.117% 
Kallmann Syndrome Recessive 17054399 PROKR2 607123 20 5294762 5294846 rs74315418 c.254G>A p.Arg85His 0 3 0.18% 0.074% 
Adenomise Deaminase Deficiency Recessive 2166947 ADA 608958 20 43255233 43255235 rs121908736 c.226C>T p.Arg76Trp 0 2 0.11% 0.035% 
Arterial Tortuosity Syndrome Recessive 18565096 SLC2A10 606145 20 45353918 45353942 rs80358230 c.243C>G p.Ser81Arg 2 15 0.95% - 
Homocystinuria Recessive 10364517 CBS 613381 21 44483184 44483437 rs5742905 c.833T>C p.Ile278Thr 0 98 4.89% 0.007% 
Leukocyte adhesion Deficiency Recessive 1346613 ITGB2 600065 21 46309312 46309674 rs5030672 c.1756C>T p.Arg586Trp 0 3 0.18% 0.755% 
Hyperprolinemia Type I Recessive 17412540 PRODH 606810 22 18905859 18905888 rs2870984 c.1397C>T p.Thr466Met 0 15 0.99% 0.573% 
Schizophrenia and mild hyperprolinemia Recessive 12217952 PRODH 606810 22 18905899 18905928 rs3970559 c.1357C>T p.Arg453Cys 0 19 1.37% 1.200% 
Schizophrenia and mild hyperprolinemia Recessive 12217952 PRODH 606810 22 18905934 18905963 rs2904551 c.1322T>C p.Leu441Pro 0 6 0.51% 0.575% 
Glucose-6-Phosphate Dehydrogenase Defi-
ciency Recessive (M) 3393536 G6PD 305900 X 153761205 153760352 rs5030869 c.1141G>A p.Ala381Thr 0 2 0.20% 0.023% 
Glucose-6-Phosphate Dehydrogenase Defi-
ciency 
Recessive (M; 
Mod) 3393536 G6PD 305900 X 153762634 153761781 rs5030868 c.563C>T p.Ser188Phe 1 47 4.20% 0.310% 
Glucose-6-Phosphate Dehydrogenase Defi-
ciency Recessive  3393536 G6PD 305900 X 153764371 153763518 rs76645461 c.143T>C p.Ile48Thr 0 4 0.37% 0.001% 
1 Curated list of known pathogenic Mendelian Disease causing mutations observed in at least 2 Qataris. Table is divided by inheritance patterns (dominant, recessive) and sorted by 
chromosome and position. Reported for each mutation is the disease it causes, the inheritance model, Pubmed ID (PMID) for the reference publication where the causality was 
initially reported, gene name, gene MIM number, variant site in GRCh37 (chromosome, position, rsID) and the effect of the mutation on cDNA and on amino acid. Also reported is 
the total number of homozygous and heterozygous Qataris observed harboring this mutation (# Q - Hom & Het, respectively), the overall frequency of the deleterious allele in 
Qataris, and allele frequency in the Exome Aggregation Consortium (ExAC, total alleles ~63,000). LO: Late Onset, SD: Semi-dominant, M: Mild, RP: Reduced Penetrance. PMID: 
Pubmed ID. MAF: Minor Allele Frequency.  Positions include both GRCh37 and QTRG3 coordinates inferred using HALtools44 liftover of GRCh37 to QTRG3 alignment pro-
duced using progressiveCactus26.
 Supplemental Figure Legends 
 
Supplemental Figure 1. Sample analysis flowchart. Shown is an overview of the major analysis 
steps and samples included in each analysis. From top to bottom and left to right, samples for se-
quencing in this study include n=215 s living in Qatar and n=1161 Qataris, defined as such based 
on 3 generations of ancestry in Qatar. Exome sequencing was conducted on n=1268 samples us-
ing Illumina instruments and two Agilent SureSelect Human All Exon kits (n=1201 and Qatari 
on the 51 Mb kit and n=67 Qatari on the 38 Mb kit), hereafter referred to as “Exome38Mb” and 
“Exome51Mb”. Genome sequencing was also conducted for n=108 Qatari samples on an Illu-
mina instrument. Variant calling was conducted for each batch of samples (Exome51Mb, Ex-
ome38Mb, genome), and combined into a preliminary SNP and indel call set. Using variant calls 
within genomic intervals covered in all three batches (within CCDS coding exons targeted by the 
Agilent SureSelect 38 Mb kit), three preliminary analyses were conducted. The preliminary anal-
ysis included (1) identification of optimal batch-specific filters, (2) identification of relatives in 
the n=1376 samples using a LD-pruned set of SNPs, and (3) population structure analysis 
(ADMIXTURE and principal components) using a subset of variants also segregating in the da-
tabase of public samples (Human Origins and 1000 Genomes). Based on the results of prelimi-
nary analysis, pruning of non-Qataris (n=215) and 1st/2nd degree relatives (n=156) resulted in 
n=1005 unrelated Qataris for further analysis, including n=917 exomes (n=64 Exome38Mb and 
n=853 Exome51Mb), and n=88 genomes. The allele frequencies of the remaining variants was 
quantified, and a comparison to dbSNP 146 was conducted to identify novel variants and enable 
database annotation of known variants. Using variants (SNPs and indels) present in over 50% of 
the n=1005 samples, the GRCh37 human reference genome was modified to incorporate these 
major alternate alleles (MAA). The value of using the modified reference, or Qatar Reference 
Genome (QTRG) was then assessed by comparing sequencing depth and variant calls for Qataris 
 not in the n=1005 used to construct the reference. In addition, a catalog of potentially pathogenic 
variants was constructed by combining the Qatari variant allele frequency information with pub-
lic database for genes and variants linked to disease and algorithms for predicting variant func-
tion and pathogenicity. 
Supplemental Figure 2. Impact of minimum depth and minimum allele count on novel SNP 
rate. A total of 1376 samples were sequenced using Illumina technology on three platforms, in-
cluding genome (n=108), exome sequencing based on enrichment using the Agilent SureSelect 
38 Mb targets (Exome38Mb, n=67), and exome sequencing based on enrichment using the Ag-
ilent SureSelect 51 Mb targets (Exome51Mb, n=1201). In order to integrate the three datasets, 
genotypes were generated for a set of variants covered by the three platforms, including CCDS 
coding exons overlapping the Exome38Mb targets. Variants were filtered using a range of mini-
mum depth and minimum allele count parameters, shown is the impact of these filters on A. 
Mean depth at variant sites, B. Mean number of variant sites per sample, and C. percentage of 
novel variants, defined as not present in DbSNP build 146. Dotted line indicates level of con-
sistent novel SNP rate. 
Supplemental Figure 3. Impact of filters on batch-specific variants. Batch-specific variants. In 
order to validate the selected minimum depth and minimum allele count for each platform, the 
proportion of batch-specific variants was compared in variant call data with and without filters 
applied. Data source is a single Qatari female DNA sample that was sequenced on four platforms 
(2 exome, 2 genome), including genome sequencing on both the Illumina HiSeq 2500 and Illu-
mina HiSeq X platforms, as well as Illumina sequencing of exome DNA enriched using the Ag-
ilent SureSelect Human All Exon 51 Mb and 38 Mb targets. Variant calls were generated using 
GATK HaplotypeCaller on the four datasets, limited to CCDS coding intervals covered by the 
four platforms (within 38 Mb targets). Shown are Venn diagrams of A. unfiltered variant sites, 
 B. unfiltered novel variant sites (not in DbSNP 146), C. filtered variant sites, and D. filtered 
novel variant sites.  
Supplemental Figure 4. Impact of filters on sensitivity. In order to determine the impact of 
batch-specific filters on sensitivity for variant detection and novel SNP rate across a range of 
depths, variant calls were generated for a quadruple sequenced Qatari using the GATK “dfrac” 
parameter, which enables variant calling on a subsampling a percentage of reads. The dfrac-
based calling was conducted for a range of values from 5% to 100%, in 5% increments. At each 
setting, calls were generated on genomic intervals overlapping between the four platforms four 
platforms (2 exome, 2 genome), including genome sequencing on both the Illumina HiSeq 2500 
and Illumina HiSeq X platforms, as well as Illumina sequencing of exome DNA enriched using 
the Agilent SureSelect Human All Exon 51 Mb and 38 Mb targets. Variant calls were generated 
using GATK HaplotypeCaller on the four datasets, limited to CCDS coding intervals covered by 
the four platforms (within 38 Mb targets). Shown is A. the total number of unfiltered variants (y-
axis) in the four platforms across a range of depths (x-axis) color-coded by platform (blue = Ex-
ome38Mb, green = Exome51Mb, red = genome on HiSeq 2500, orange = genome on HiSeq X). 
B. total number of filtered variants (y-axis) in the four platforms across a range of depths (x-
axis), C. the proportion of unfiltered novel variants (y-axis) in the four platforms across a range 
of depths (x-axis), and D. the proportion of filtered novel variants (y-axis) in the four platforms 
across a range of depths (x-axis). 
Supplemental Figure 5. Dominant ancestries. In order to infer the dominant ancestry of each of 
the n=1161 Qatari samples included in this study, and ADMIXTURE analysis was conducted on 
n=5611 samples, including the n=1161 Qataris included in this study, the n=215 s sampled in 
Qatar, the Human Origins data (n=1862), and the 1000 Genomes Phase 3 data (n=2373 not in 
Human Origins). Integration of the datasets resulted in n=2256 SNPs present in all three (n=1376 
 from this study, Human Origins, and 1000 Genomes). The ADMIXTURE analysis was con-
ducted with K=12, determined to be optimal in a prior study17, resulting in admixture proportions 
in 12 ancestral populations for each individual. Individuals were assigned to an ancestral popula-
tion based on their dominant ancestry, and cluster names were assigned based on the major popu-
lations present in these clusters. Shown is the ancestry proportion in A. the full dataset (n=5611), 
and a detailed view of the results from the same analysis in B. the n=1161 Qatari.  
Supplemental Figure 6. Principal components analysis. In order to confirm the observed popu-
lation structure inferred using ADMIXTURE16,26, a principal components (PC) analysis45 was 
conducted on the n=5611 samples, including n=1161 Qataris, n=215 s living in Qatar, n=1862 
Human Origins samples, and n=2373 1000 Genomes Phase 3 samples not in Human Origins. 
Analysis was conducted using the same n=2256 SNPs used in the ADMIXTURE16,26 analysis. 
Each individual is color-coded based on their dominant ancestry (K cluster), with names as-
signed based on the major populations in the cluster (K=1 European, K=2 East Asian, K=3 Sibe-
rian, K=4 South Asian, K=5 Bedouin, K=6 African Pygmy, K=7 Oceanian, K=8 Arab, K=9 Per-
sian, K=10 Sub-Saharan African, K=11 American, K=12 Central Asian). Shown is a plot of A. 
PC1 vs PC2 and B. PC2 vs PC3. 
Supplemental Figure 7. Relatives in Qatar. In order to compare inferred pedigree sizes between 
Qataris and non-Qataris, a graph of inferred relatives was produced. Shown are inferred pedi-
grees for A. Qataris and B. s, in order of decreasing size. Relationships were inferred between 
n=1376 samples (including Qataris and s) as described in the Supplemental Methods and Sum-
marized in Supplemental Table IV. Each node represents and individual, and the line connecting 
two individuals represents the relationship (1st degree = straight line, 2nd degree = wavy line, 3rd 
degree = dotted line). The nodes are color-coded based on the inferred dominant ancestry in the 
ADMIXTURE16,26 analysis.  
 Online Resources 
 
Online Resource 1. Prevalence and Function of Qatari Variants. Tab-delimited file including 
allele frequency in the Qatari population, number of homozygous and heterozygous individuals, 
functional annotation, and links to databases of gene and variant function for 20.9 million SNPs 
identified in 88 unrelated Qatari genomes 917 unrelated Qatari exomes. Available for download 
is the full list of variants, as well as subsets of category 1, category 2, and category 3 variants, as 
described in Table II. Variant database can be accessed at http://geneticmedicine.weill.cor-
nell.edu/Genome/Online.Resource.1/ 
  
 Online Resource 2. Qatari Reference Genome (QTRG1, QTRG2, QTRG3). Human refer-
ence genome based on GRCh37 where the major alternate allele identified in 88 unrelated Qatari 
genomes 917 unrelated Qatari exomes replaced the reference allele SNP and indel sites. Accessi-
ble at http://geneticmedicine.weill.cornell.edu/Genome/Online.Resource.2/. 
  
 Online Resource 3. Precision medicine tools for Qatari genomes. Genome interpretation anal-
ysis workflow based on GATK Best Practices8 for an individual Qatari genome, coded in Py-
thon. Accessible at http://geneticmedicine.weill.cornell.edu/Genome/Online.Resource.3/. 
  
 Online Resource 4. All variants observed in unrelated Qataris. Genotypes for variant sites 
(with respect to GRCh37) observed in 1376 Qataris, in VCF format before application of plat-
form specific filters. Accessible at http://geneticmedicine.weill.cornell.edu/Genome/Online.Re-
source.4/. 
  
 Online Resource 5. Segregating sites in unrelated Qataris. Genotypes for variant sites poly-
morphic in 1005 unrelated Qataris, in PLINK format12. Accessible at http://geneticmedi-
cine.weill.cornell.edu/Genome/Online.Resource.5/. 
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Phase 3, and Human Origins (n=5611), color-coded by dominant ancestry cluster (K)
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